Prof. Dr. MUSTAFA ÖZGÜROĞLU

Metrikler

Yayın

540

Yayın (WoS)

467

Yayın (Scopus)

371

Atıf (WoS)

29273

H-İndeks (WoS)

Atıf (Scopus)

31499

H-İndeks (Scopus)

Atıf (Scholar)

33898

H-İndeks (Scholar)

Proje

Açık Erişim

BM Sürdürülebilir Kalkınma Amaçları

Eğitim Bilgileri

1993 - 1996

Tıpta Yandal Uzmanlık

İstanbul Üniversitesi, Cerrahpaşa Tıp Fakültesi, Tıbbi Onkoloji, Türkiye

1988 - 1993

Tıpta Uzmanlık

İstanbul Üniversitesi, Cerrahpaşa Tıp Fakültesi, İç Hastalıkları , Türkiye

Yabancı Diller

B1 Orta

Fransızca

C1 İleri

İngilizce

Araştırma Alanları

Tıp

Dahili Tıp Bilimleri

İç Hastalıkları

Onkoloji

Sağlık Bilimleri

Akademik Faaliyetlere Dayalı Araştırma Alanları

Avesis Araştırma Alanları

WoS Araştırma Alanları

Scopus Araştırma Alanları

Akademik Ünvanlar / Görevler

1988 - Devam Ediyor

Prof. Dr.

İstanbul Üniversitesi, Dahili Bilimler

Tanıtım ve Temsil Faaliyetleri

Nomination to SIGMA X1

Kurumsal Tanıtım, SIGMA X1, Türkiye, İstanbul, 2025 - 2026

Makaleler

2026

1. Review of patient-reported outcomes in EMPOWER-Lung 1 in patients with advanced non-small cell lung cancer treated with cemiplimab versus chemotherapy.

Gandara D. R., Gümüş M., Kilickap S., Sezer A., Bondarenko I., Özgüroğlu M., et al.

Cancer , cilt.132, sa.6, 2026 (SCI-Expanded, Scopus)

2026

2. Time to subsequent chemotherapy with capivasertib (capi) plus abiraterone (abi) versus placebo (pbo) plus abi in patients (pts) with PTEN deficient metastatic hormone-sensitive prostate cancer (mHSPC): CAPItello-281

Clarke N., George D. J., De Santis M., Uemura H., Fay A. P., Karadurmus N., et al.

EUROPEAN UROLOGY , cilt.89, 2026 (SCI-Expanded, Scopus)

2026

3. Patient-Reported Outcomes with Consolidation Durvalumab Versus Placebo Following Concurrent Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer: Results from the Phase 3 ADRIATIC Trial.

Novello S., Cheng Y., Spigel D., Fang J., Chen Y., Zenke Y., et al.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer , ss.103564, 2026 (SCI-Expanded, Scopus)

2026

4. Prognostic role of smoking in metastatic renal cell carcinoma in real-world data from the Turkish Oncology Group Kidney Cancer Consortium (TKCC).

Bolek H., Sertesen Camoz E., Kuzu O. F., Karakas H., Sim S., Sekmek S., et al.

Scientific reports , 2026 (SCI-Expanded, Scopus)

2026

5. Erratum: Simultaneous Durvalumab and Platinum-Based Chemoradiotherapy in Unresectable Stage III Non-Small Cell Lung Cancer: The Phase III PACIFIC-2 Study.

Bradley J. D., Sugawara S., Lee K. H., Ostoros G., Demirkazik A., Zemanova M., et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology , 2026 (SCI-Expanded, Scopus)

2025

6. First-Line Cemiplimab for Locally Advanced NSCLC: Updated Subgroup Analyses From the EMPOWER-Lung 1 and EMPOWER-Lung 3 Trials.

Kalinka E., Bondarenko I., Gogishvili M., Melkadze T., Baramidze A., Sezer A., et al.

JTO clinical and research reports , cilt.7, sa.4, ss.100947, 2025 (ESCI, Scopus)

2025

7. Durvalumab Plus Platinum-Etoposide in Extensive-Stage Small-Cell Lung Cancer: Outcomes in Age, Sex, and Platinum Subgroups From the Phase 3 CASPIAN Study.

Reinmuth N., Goldman J. W., Chen Y., Hotta K., Trukhin D., Statsenko G., et al.

Clinical lung cancer , cilt.26, ss.626-641, 2025 (SCI-Expanded, Scopus)

2025

8. 212eP Optimizing diagnostic approach and steroid use in GI toxicities associated with immune checkpoint inhibitors: A single center experience

Cerme E., Birsin Z., Guliyev M., Alkan G., Ögüt G., Hatemi I., et al.

Immuno-Oncology and Technology , cilt.28, ss.1, 2025 (Scopus)

2025

9. Patient-reported Outcomes for Men with Metastatic Castration-resistant Prostate Cancer Who Received Olaparib plus Abiraterone Versus Placebo plus Abiraterone in the Phase 3 PROpel Study.

Armstrong A. J., Saad F., Oya M., Vianna K., Özgüroğlu M., Gedye C., et al.

European urology oncology , 2025 (SCI-Expanded, Scopus)

2025

10. Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial.

Attard G., Agarwal N., Graff J. N., Sandhu S., Efstathiou E., Özgüroğlu M., et al.

Nature medicine , 2025 (SCI-Expanded, Scopus)

2025

11. Phase 3 AMPLITUDE trIal: NIraparIb (NIRA) and abIraterone acetate plus prednIsone (AAP) for metastatIc castratIon-sensItIve prostate cancer (mCSPC) patIents (pts) wIth alteratIons In homologous recombInatIon repaIr (HRR) genes

Heidenreich A., Attard G., Agarwal N., Graff J. N., Sandhu S., Efstathiou E., et al.

ONCOLOGY RESEARCH AND TREATMENT , cilt.48, sa.SUPPL 2, 2025 (SCI-Expanded, Scopus)

2025

12. Pembrolizumab plus enzalutamide and androgen deprivation therapy versus placebo plus enzalutamide and androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: the randomized, double-blind, phase III KEYNOTE-991 study.

Gratzke C., Özgüroğlu M., Peer A., Sendur M. A. N., Retz M., Goh J. C., et al.

Annals of oncology : official journal of the European Society for Medical Oncology , cilt.36, ss.964-975, 2025 (SCI-Expanded, Scopus)

2025

13. Cemiplimab Monotherapy for First-Line Treatment of Patients with Advanced NSCLC with PD-L1 Expression ≥50%: 5-Year Outcomes of EMPOWER-Lung 1.

Kilickap S., Baramidze A., Sezer A., Özgüroğlu M., Gumus M., Bondarenko I., et al.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer , cilt.20, ss.941-954, 2025 (SCI-Expanded, Scopus)

2025

14. The Impact of Smoking on Nivolumab Outcomes in Renal Cell Carcinoma: Real-World Data from the Turkish Oncology Group Kidney Cancer Consortium (TKCC).

Sertesen Camoz E., Bolek H., Kuzu O. F., Sim S., Karakaş H., Sekmek S., et al.

The oncologist , cilt.30, 2025 (SCI-Expanded, Scopus)

2025

15. Clinical and molecular characteristics of early progressors (EPs) and long-term progression-free survivors (LTPs) from the phase 3 ADRIATIC trial of consolidation durvalumab (D) vs placebo (P) after concurrent chemoradiotherapy (cCRT) in limited-stage small-cell lung cancer (LS-SCLC)

Barbie D. A., Xie M., Broggi M., Cheng Y., Spigel D. R., Cho B. C., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.43, sa.16_SUPPL, 2025 (SCI-Expanded, Scopus)

2025

16. Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer.

Herbst R. S., John T., Grohé C., Goldman J. W., Kato T., Laktionov K., et al.

Nature medicine , cilt.31, ss.1958-1968, 2025 (SCI-Expanded, Scopus)

2025

17. Types and prognosis in peripheral nervous system involvement related to immune checkpoint inhibitors

Iris M., Birsin Z., TURNA Z. H., Adatepe N. U., ÖZGÜROĞLU M., Guenduez A.

EUROPEAN JOURNAL OF NEUROLOGY , cilt.32, 2025 (SCI-Expanded, Scopus)

2025

18. Cemiplimab monotherapy as first-line treatment of patients with brain metastases from advanced non-small cell lung cancer with programmed cell death-ligand 1 ≥50.

Kilickap S., Özgüroğlu M., Sezer A., Gümüş M., Bondarenko I., Gogishvili M., et al.

Cancer , cilt.131, sa.10, 2025 (SCI-Expanded, Scopus)

2025

19. Navigating second-line therapy in metastatic renal cell carcinoma: a comparative analysis of immune checkpoint inhibitors and tyrosine kinase inhibitors: a study of Turkish Oncology Group Kidney Cancer Consortium.

Aykan M. B., Bölek H., Yekedüz E., Sertesen E., Tural D., Karaçin C., et al.

Therapeutic advances in medical oncology , cilt.17, 2025 (SCI-Expanded, Scopus)

2025

20. Evaluation of tusamitamab ravtansine, a CEACAM5-targeting antibody drug conjugate, in non-squamous NSCLC participants with negative or moderate CEACAM5 expression and high circulating CEA: Results from phase II CARMEN-LC06 trial

Lena H., Paz-Ares L., Harputluoglu H., Wauters E., Rossi S., ÖZGÜROĞLU M., et al.

JOURNAL OF THORACIC ONCOLOGY , cilt.20, sa.3, 2025 (SCI-Expanded, Scopus)

2025

21. First-line (1L) durvalumab (D) plus platinum-etoposide (EP) in extensive-stage SCLC (ES-SCLC): Final results and exploratory biomarker analyses from LUMINANCE

Reinmuth N., ÖZGÜROĞLU M., Leighl N., Longo V., Hacibekiroglu I., Roubec J., et al.

JOURNAL OF THORACIC ONCOLOGY , cilt.20, sa.3, 2025 (SCI-Expanded, Scopus)

2025

22. Continued cemiplimab with addition of chemotherapy beyond progression in patients with advanced NSCLC on 1L cemiplimab monotherapy: 5-year outcomes of EMPOWER-Lung 1

Garassino M. C., Baramidze A., Kilickap S., Sezer A., ÖZGÜROĞLU M., Gumus M., et al.

JOURNAL OF THORACIC ONCOLOGY , cilt.20, sa.3, 2025 (SCI-Expanded, Scopus)

2025

23. Patient-reported outcomes (PROs) from the LAURA study: Osimertinib (osi) in patients with unresectable (UR) stage III EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC) without progression after definitive chemoradiotherapy (CRT)

Aperribay E., Casarini I., ÖZGÜROĞLU M., Huang M., Takahashi T., Lai X., et al.

JOURNAL OF THORACIC ONCOLOGY , cilt.20, sa.3, 2025 (SCI-Expanded, Scopus)

2025

24. Osimertinib (osi) after definitive chemoradiotherapy (CRT) in patients (pts) with unresectable (UR) stage III EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC): Updated overall survival (OS) analysis from the LAURA study

Ramalingam S. S., ÖZGÜROĞLU M., Ahn M., Dong X., Yang J. c., Oizumi S., et al.

JOURNAL OF THORACIC ONCOLOGY , cilt.20, sa.3, 2025 (SCI-Expanded, Scopus)

2025

25. Effects of immune related adverse events and corticosteroids on the outcome of patients treated with immune checkpoint inhibitors

Şen G. A., Öztaş N. Ş., Değerli E., Safarov S., Guliyev M., Bedir Ş., et al.

SCIENTIFIC REPORTS , cilt.15, sa.1, 2025 (SCI-Expanded, Scopus)

2025

26. Simultaneous Durvalumab and Platinum-Based Chemoradiotherapy in Unresectable Stage III Non-Small Cell Lung Cancer: The Phase III PACIFIC-2 Study.

Bradley J. D., Sugawara S., Lee K. H., Ostoros G., Demirkazik A., Zemanova M., et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology , ss.1-14, 2025 (SCI-Expanded, Scopus)

2025

27. Adverse events self-reported by patients with extensive-stage small-cell lung cancer in the phase III CASPIAN study.

Özgüroğlu M., Goldman J. W., Chen Y., Garassino M. C., Medic N., Mann H., et al.

Future oncology (London, England) , cilt.21, ss.1511-1523, 2025 (SCI-Expanded, Scopus)

2024

28. Effect of body mass index on immune checkpoint inhibitor efficacy in patients with advanced cancer.

Alkan Şen G., Şentürk Öztaş N., Değerli E., Guliyev M., Turna H., Özgüroğlu M.

Tumori , cilt.110, sa.6, ss.437-442, 2024 (SCI-Expanded, Scopus)

2024

29. 616P Osimertinib after definitive chemoradiotherapy (CRT) in patients (pts) with unresectable (UR) stage III epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC): Post-progression outcomes from the phase III LAURA study

Ozguroglu M., Ahn M., Dong X., Yang J., Oizumi S., Goto K., et al.

ANNALS OF ONCOLOGY , cilt.35, ss.1, 2024 (SCI-Expanded, Scopus)

2024

30. Hyperprogressive disease in patients with advanced cancer treated with immune checkpoint inhibitors.

Şen G. A., Öztaş N. Ş., Değerli E., Guliyev M., Can G., Turna H., et al.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico , cilt.26, sa.12, ss.3264-3271, 2024 (SCI-Expanded, Scopus)

2024

31. Treatment Patterns and Attrition in Metastatic Renal Cell Carcinoma: Real-Life Experience from the Turkish Oncology Group Kidney Cancer Consortium (TKCC) Database.

Bölek H., Sertesen E., Kuzu O. F., Tural D., Sim S., Nahit Şendur M. A., et al.

Clinical genitourinary cancer , cilt.23, sa.1, ss.102282, 2024 (SCI-Expanded, Scopus)

2024

32. Cisplatin- or Carboplatin-Based Chemotherapy Plus Pembrolizumab in Advanced Urothelial Cancer: Exploratory Analysis From the Phase 3 KEYNOTE-361 Study.

Powles T., Csőszi T., Loriot Y., Matsubara N., Geczi L., Cheng S. Y., et al.

Clinical genitourinary cancer , cilt.23, sa.1, ss.102261, 2024 (SCI-Expanded, Scopus)

2024

33. Association of Tumor Mutational Burden and PD-L1 with the Efficacy of Pembrolizumab with or without Chemotherapy versus Chemotherapy in Advanced Urothelial Carcinoma.

Fléchon A., Morales-Barrera R., Powles T., Alva A., Özgüroğlu M., Csöszi T., et al.

Clinical cancer research : an official journal of the American Association for Cancer Research , 2024 (SCI-Expanded, Scopus)

2024

34. Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study

Leighl N. B., Akamatsu H., Lim S. M., Cheng Y., Minchom A. R., Marmarelis M. E., et al.

Journal of Clinical Oncology , cilt.42, sa.30, ss.3593-3605, 2024 (SCI-Expanded, Scopus)

2024

35. Patient-Reported Outcomes (PROs) With Consolidation Durvalumab Versus Placebo Following cCRT in Limited-Stage SCLC: ADRIATIC

Novello S., Cheng Y., Spigel D., Fang J., Chen Y., Zenke Y., et al.

JOURNAL OF THORACIC ONCOLOGY , sa.10, 2024 (SCI-Expanded, Scopus)

2024

36. Cemiplimab Monotherapy for First Line Advanced NSCLC Patients with PD-L1 Expression ≥50%: 5-y Outcomes of EMPOWER-Lung 1

Kilickap S., Sezer A., Ozguroglu M., GÜMÜŞ M., Bondarenko I., Gogishvili M., et al.

JOURNAL OF THORACIC ONCOLOGY , sa.10, 2024 (SCI-Expanded, Scopus)

2024

37. Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer.

Powles T., Catto J. W. F., Galsky M. D., Al-Ahmadie H., Meeks J. J., Nishiyama H., et al.

The New England journal of medicine , 2024 (SCI-Expanded, Scopus)

2024

38. Osimertinib after definitive chemoradiotherapy in unresectable stage III epidermal growth factor receptor-mutated non-small-cell lung cancer: analyses of central nervous system efficacy and distant progression from the phase III LAURA study.

Lu S., Ahn M., Reungwetwattana T., Özgüroğlu M., Kato T., Yang J. C., et al.

Annals of oncology : official journal of the European Society for Medical Oncology , 2024 (SCI-Expanded, Scopus)

2024

39. Molecularly guided therapy versus chemotherapy after disease control in unfavourable cancer of unknown primary (CUPISCO): an open-label, randomised, phase 2 study.

Krämer A., Bochtler T., Pauli C., Shiu K., Cook N., de Menezes J. J., et al.

Lancet (London, England) , cilt.404, sa.10452, ss.527-539, 2024 (SCI-Expanded, Scopus)

2024

40. Association of baseline characteristics with adverse events (AEs) in the PROpel trial of olaparib (ola) plus abiraterone (abi) as first-line (1L) treatment for metastatic castration-resistant prostate cancer (mCRPC)

Armstrong A. J., Saad F., Oya M., Shore N. D., Procopio G., Vianna K., et al.

JOURNAL OF CLINICAL ONCOLOGY , sa.16, 2024 (SCI-Expanded, Scopus)

2024

41. Perceptions and expectations: A study on prognostic perception and quality of life in patients with metastatic renal and bladder cancer.

Bolek H., Arslan C., Basaran M., Cicin I., Ozguroglu M., Tural D., et al.

JOURNAL OF CLINICAL ONCOLOGY , sa.16, 2024 (SCI-Expanded, Scopus)

2024

42. Vibostolimab coformulated with pembrolizumab (vibo/pembro) for previously treated advanced mismatch repair-deficient (dMMR) endometrial cancer: Results from cohort B1 of the phase 2 KEYVIBE-005 study

Rojas C., Eskens F., Ghiringhelli F., Ozguroglu M., Caglevic C., Gumus M., et al.

JOURNAL OF CLINICAL ONCOLOGY , sa.16, 2024 (SCI-Expanded, Scopus)

2024

43. Osimertinib (osi) after definitive chemoradiotherapy (CRT) in patients (pts) with unresectable stage (stg) III epidermal growth factor receptor-mutated (EGFRm) NSCLC: Primary results of the phase 3 LAURA study

Ramalingam S. S., Kato T., Dong X., Ahn M., Quang L., Soparattanapaisarn N., et al.

JOURNAL OF CLINICAL ONCOLOGY , sa.17_SUPPL, 2024 (SCI-Expanded, Scopus)

2024

44. **Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC**

Lu S., Kato T., Dong X., Ahn M., Quang L., Soparattanapaisarn N., et al.

NEW ENGLAND JOURNAL OF MEDICINE , 2024 (SCI-Expanded, Scopus)

2024

45. Tolerability of Olaparib Combined with Abiraterone in Patients with Metastatic Castration-resistant Prostate Cancer: Further Results from the Phase 3 PROpel Trial.

Saad F., Armstrong A. J., Oya M., Vianna K., Özgüroğlu M., Gedye C., et al.

European urology oncology , 2024 (SCI-Expanded, Scopus)

2024

46. Safety and efficacy of nivolumab therapy in patients with metastatic renal cell carcinoma and impaired kidney function.

Sengul N., Gültürk I., Yilmaz M., Celik E., Paksoy N., Yekedüz E., et al.

Actas urologicas espanolas , 2024 (SCI-Expanded)

2024

47. Prostate-specific antigen (PSA) decline with apalutamide therapy is associated with longer survival and improved outcomes in individuals with metastatic prostate cancer: a plain language summary of the TITAN study.

Chowdhury S., Bjartell A., Agarwal N., Chung B. H., Given R. W., Pereira de Santana Gomes A. J., et al.

Future oncology (London, England) , cilt.20, ss.563-578, 2024 (SCI-Expanded, Scopus)

2024

48. Symptomatic Pneumonitis With Durvalumab After Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC

Vansteenkiste J. F., Naidoo J., Faivre-Finn C., ÖZGÜROĞLU M., Villegas A., Daniel D., et al.

JTO Clinical and Research Reports , cilt.5, sa.3, 2024 (ESCI, Scopus)

2024

49. Durvalumab ± tremelimumab + platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): outcomes by PD-L1 expression and tissue tumor mutational burden.

Paz-Ares L., Garassino M. C., Chen Y., Reinmuth N., Hotta K., Poltoratskiy A., et al.

Clinical cancer research : an official journal of the American Association for Cancer Research , cilt.30, ss.824-835, 2024 (SCI-Expanded, Scopus)

2024

50. Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in BRCA1 and/or BRCA2 in the PROfound Trial.

Mateo J., de Bono J. S., Fizazi K., Saad F., Shore N., Sandhu S., et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology , cilt.42, ss.571-583, 2024 (SCI-Expanded, Scopus)

2024

51. Primary analysis of efficacy and safety in the CUPISCO trial: A randomised, global study of targeted therapy or cancer immunotherapy guided by comprehensive genomic profiling (CGP) vs platinum-based chemotherapy (CTX) in newly diagnosed, unfavourable cancer of unknown primary (CUP)

Kraemer A., Mileshkin L., Bochtler T., Pauli C., Duran-Pacheco G., Arslan C., et al.

ONCOLOGY RESEARCH AND TREATMENT , ss.234-235, 2024 (SCI-Expanded, Scopus)

2024

52. Avelumab vs platinum-based doublet chemotherapy as first-line treatment for patients with high-expression PD-L1+ metastatic non-small cell lung cancer: primary analysis from the phase 3 JAVELIN Lung 100 trial.

Reck M., Barlesi F., Chih-Hsin Yang J., Westeel V., Felip E., Özgüroğlu M., et al.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer , cilt.19, sa.2, ss.297-313, 2024 (SCI-Expanded, Scopus)

2024

53. Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial.

Siefker-Radtke A. O., Matsubara N., Park S. H., Huddart R. A., Burgess E. F., Özgüroğlu M., et al.

Annals of oncology : official journal of the European Society for Medical Oncology , cilt.35, sa.1, ss.107-117, 2024 (SCI-Expanded, Scopus)

2024

54. Evaluation of the efficacy and safety of nivolumab in the second- or later-line treatment of patients with locally advanced/metastatic non-small cell lung cancer in Türkiye: a retrospective multicenter non-interventional registry study.

Karadurmus N., Kaplan M. A., Sendur M. A. N., Urun Y., Demirci U., Karaca S. B., et al.

Current medical research and opinion , cilt.40, sa.7, ss.1171-1178, 2024 (SCI-Expanded, Scopus)

2024

55. Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis from a randomised, controlled, phase 3 study.

Bamias A., Davis I. D., Galsky M. D., Arranz J. Á., Kikuchi E., Grande E., et al.

The Lancet. Oncology , cilt.25, sa.1, ss.46-61, 2024 (SCI-Expanded, Scopus)

2023

56. Targeted treatment for unresectable EGFR mutation-positive stage III non-small cell lung cancer: Emerging evidence and future perspectives.

Kato T., Casarini I., Cobo M., Faivre-Finn C., Hegi-Johnson F., Lu S., et al.

Lung cancer (Amsterdam, Netherlands) , cilt.187, ss.107414, 2023 (SCI-Expanded, Scopus)

2023

57. Disease Progression on PROs in Patients With aNSCLC With PD-L1 ≥50% Receiving Cemiplimab vs Chemotherapy: EMPOWER-Lung 1

GÜMÜŞ M., Kilickap S., Sezer A., Bondarenko I., ÖZGÜROĞLU M., Gogishvili M., et al.

JOURNAL OF THORACIC ONCOLOGY , sa.11, 2023 (SCI-Expanded, Scopus)

2023

58. Effect of antibiotic treatment on immune checkpoint inhibitors efficacy in patients with advanced non-small cell lung cancer

Alkan Şen G., Şentürk Öztaş N., Değerli E., Can G., Turna H., Özgüroğlu M.

Lung Cancer , cilt.184, 2023 (SCI-Expanded, Scopus)

2023

59. LBA16 Primary analysis of efficacy and safety in the CUPISCO trial: A randomised, global study of targeted therapy or cancer immunotherapy guided by comprehensive genomic profiling (CGP) vs platinum-based chemotherapy (CTX) in newly diagnosed, unfavourable cancer of unknown primary (CUP)

Mileshkin L., Bochtler T., Pauli C., Durán-Pacheco G., Arslan C., Bigot F., et al.

ANNALS OF ONCOLOGY , cilt.34, ss.1, 2023 (SCI-Expanded, Scopus)

2023

60. First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial.

Özgüroğlu M., Kilickap S., Sezer A., Gümüş M., Bondarenko I., Gogishvili M., et al.

The Lancet. Oncology , cilt.24, ss.989-1001, 2023 (SCI-Expanded, Scopus)

2023

61. Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer

Chi K. N., Rathkopf D., Smith M. R., Efstathiou E., Attard G., Olmos D., et al.

Journal of Clinical Oncology , cilt.41, sa.18, ss.3339-3351, 2023 (SCI-Expanded, Scopus)

2023

62. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial

Kelley R. K., Ueno M., Yoo C., Finn R. S., Furuse J., Ren Z., et al.

The Lancet , cilt.401, sa.10391, ss.1853-1865, 2023 (SCI-Expanded, Scopus)

2023

63. Clinical Features and Prognostic Factors of Metastatic Non-Clear Cell Renal Cell Carcinoma: A Multicenter Study from the Turkish Oncology Group Kidney Cancer Consortium.

Erol C., Yekedüz E., Tural D., Karakaya S., Şentürk Öztaş N., Uçar G., et al.

Urologia internationalis , cilt.107, sa.6, ss.595-601, 2023 (SCI-Expanded, Scopus)

2023

64. Association between gene expression signatures and clinical outcomes of pembrolizumab versus paclitaxel in advanced gastric cancer: exploratory analysis from the randomized, controlled, phase III KEYNOTE-061 trial.

Shitara K., Di Bartolomeo M., Mandala M., Ryu M., Caglevic C., Olesinski T., et al.

Journal for immunotherapy of cancer , cilt.11, sa.6, 2023 (SCI-Expanded, Scopus)

2023

65. Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer.

Chowdhury S., Bjartell A., Agarwal N., Chung B. H., Given R. W., Pereira de Santana Gomes A. J., et al.

Annals of oncology : official journal of the European Society for Medical Oncology , cilt.34, ss.477-485, 2023 (SCI-Expanded, Scopus)

2023

66. 149P HER2-low status and response to neoadjuvant chemotherapy in early breast cancer

Alkan G., Oztas N. S., Degerli E., Safarov S., Guliyev M., Gunaltili M., et al.

ESMO OPEN , cilt.8, sa.1, ss.1-5, 2023 (SCI-Expanded, Scopus)

2023

67. EMPOWER-Lung 1: Cemiplimab (CEMI) monotherapy as first-line (1L) treatment of patients ( pts) with brain metastases from advanced non-small cell lung cancer (aNSCLC) with programmed cell death-ligand 1 (PD-L1) ≥50%-3-year update

Kilickap S., Ozguroglu M., Sezer A., Gumus M., Bondarenko I., Gogishvili M., et al.

JOURNAL OF THORACIC ONCOLOGY , sa.4, 2023 (SCI-Expanded, Scopus)

2023

68. First-line cemiplimab for locally advanced non-small cell lung cancer: Updated subgroup analyses from EMPOWER-Lung 1 and EMPOWER-Lung 3

Kalinka E., Bondarenko I., Gogishvili M., Melkadze T., Baramidze A., Sezer A., et al.

JOURNAL OF THORACIC ONCOLOGY , sa.4, 2023 (SCI-Expanded, Scopus)

2023

69. Preliminary results from LUMINANCE: A phase IIIb, single-arm study of 1L durvalumab (D) plus platinum-etoposide (EP) for patients with extensive-stage SCLC (ES-SCLC)

Reinmuth N., de Marinis F., Leighl N., Sadow S., Davey K., ÖZGÜROĞLU M.

JOURNAL OF THORACIC ONCOLOGY , sa.4, 2023 (SCI-Expanded, Scopus)

2023

70. Three-year Outcomes per PD-L1 Status and Continued Cemiplimab Beyond Progression plus Chemotherapy: EMPOWER-Lung 1

Garassino M. C., Kilickap S., Ozguroglu M., Sezer A., Gumus M., Bondarenko I., et al.

JOURNAL OF THORACIC ONCOLOGY , sa.3, 2023 (SCI-Expanded, Scopus)

2023

71. External Validation of a Novel Risk Model in Patients With Favorable Risk Renal Cell Carcinoma Defined by International Metastatic Renal Cell Carcinoma Database Consortium (IMDC): Results From the Turkish Oncology Group Kidney Cancer Consortium (TKCC) Database.

Yekedüz E., Karakaya S., Ertürk İ., Tural D., Uçar G., Şentürk Öztaş N., et al.

Clinical genitourinary cancer , cilt.21, sa.1, ss.175-182, 2023 (SCI-Expanded, Scopus)

2023

72. Patient-reported outcomes with cemiplimab monotherapy for first-line treatment of advanced non-small cell lung cancer with PD-L1 of ≥50%: The EMPOWER-Lung 1 study.

Gümüş M., Chen C., Ivanescu C., Kilickap S., Bondarenko I., Özgüroğlu M., et al.

Cancer , cilt.129, ss.118-129, 2023 (SCI-Expanded, Scopus)

2022

73. 112P Pseudoprogression predicts better prognosis in advanced non-small cell lung cancer treated with immune checkpoint inhibitors

Senturk Oztas N., Alkan G., Degerli E., Turna Z. H., Ozguroglu M.

Immuno-Oncology and Technology , cilt.16, ss.1, 2022 (Düzenli olarak gerçekleştirilen hakemli kongrenin bildiri kitabı)

2022

74. 94P Does hyperprogressive disease predict poor survival?

Alkan G., Senturk Oztas N., Degerli E., Turna Z. H., Ozguroglu M.

Immuno-Oncology and Technology , cilt.16, ss.1, 2022 (Düzenli olarak gerçekleştirilen hakemli kongrenin bildiri kitabı)

2022

75. Durvalumab (D) +/- tremelimumab (T) plus platinum-etoposide (EP) in 1L extensive-stage (ES) SCLC: characteristics of long-term survivors in the CASPIAN study

Goldman J. W., Garassino M. C., Chen Y., Hotta K., Poltoratskiy A., Hochmair M. J., et al.

ONCOLOGY RESEARCH AND TREATMENT , cilt.45, sa.SUPPL 3, ss.161, 2022 (SCI-Expanded, Scopus)

2022

76. Durvalumab (D) plus platinum-etoposide (EP) in first-line extensive-stage SCLC (ES SCLC): Effect of age and platinum agent on outcomes in CASPIAN

Reinmuth N., Goldman J. W., Chen Y., Hotta K., Statsenko G., Hochmair M. J., et al.

ANNALS OF ONCOLOGY , cilt.33, sa.7, 2022 (SCI-Expanded, Scopus)

2022

77. 1168P Effect of antibiotic treatment on immune checkpoint inhibitor efficacy in patients with advanced non-small cell lung cancer

Alkan G., Senturk Oztas N., Turna Z. H., Ozguroglu M.

ANNALS OF ONCOLOGY , cilt.33, ss.1, 2022 (SCI-Expanded, Scopus)

2022

78. Durvalumab (D) +/- Tremelimumab (T) plus Platinum Etoposide (EP) in 1L extensive-stage (ES) SCLC: Characteristics of Patients with Long-term Survival in the CASPIAN Study

Reinmuth N., Goldman J. W., Garassino M. C., Chen Y., Hotta K., Hochmair M. J., et al.

ONCOLOGY RESEARCH AND TREATMENT , cilt.45, sa.SUPPL 2, ss.101-102, 2022 (SCI-Expanded, Scopus)

2022

79. Detection of mutations in homologous recombination repair (HRR) genes in tumour tissue (TT) and circulating tumour DNA (ctDNA) from patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) in the phase III PROpel trial

Armstrong A. J., Saad F., Thiery-Vuillemin A., Oya M., Shore N. D., Mehra N., et al.

ANNALS OF ONCOLOGY , cilt.33, sa.7, 2022 (SCI-Expanded, Scopus)

2022

80. Patient-reported Outcomes of Cemiplimab versus Chemotherapy in Advanced NSCLC: PD-L1 Level Subgroups in EMPOWER-Lung 1

Kilickap S., Sezer A., Gumus M., Bondarenko I., Ozguroglu M., Gogishvili M., et al.

JOURNAL OF THORACIC ONCOLOGY , cilt.17, sa.9, 2022 (SCI-Expanded, Scopus)

2022

81. Avelumab vs Chemotherapy for First-line Treatment of Advanced PD-L1+NSCLC: Primary Analysis from JAVELIN Lung 100

Reck M., Barlesi F., Yang J. C. -., Westeel V., Felip E., Ozguroglu M., et al.

JOURNAL OF THORACIC ONCOLOGY , cilt.17, sa.9, 2022 (SCI-Expanded, Scopus)

2022

82. LUMINANCE: A Phase IIIb Study of Durvalumab plus Platinum-Etoposide for First-Line Treatment of Extensive-Stage SCLC (ES-SCLC)

Reinmuth N., DeMarinis F., Leighl N., Sadow S., Davey K., Ozguroglu M.

JOURNAL OF THORACIC ONCOLOGY , cilt.17, sa.9, 2022 (SCI-Expanded, Scopus)

2022

83. Effect of antibiotic treatment on immune checkpoint inhibitor efficacy in patients with advanced non-small cell lung cancer

Alkan G., Oztas N. S., Turna Z. H., Ozguroglu M.

ANNALS OF ONCOLOGY , cilt.33, sa.7, 2022 (SCI-Expanded, Scopus)

2022

84. Three years survival outcome and continued cemiplimab (CEMI) beyond progression with the addition of chemotherapy (chemo) for patients (pts) with advanced non-small cell lung cancer (NSCLC): The EMPOWER-Lung 1 trial

Ozguroglu M., Kilickap S., Sezer A., Gumus M., Bondarenko I., Gogishvili M., et al.

ANNALS OF ONCOLOGY , cilt.33, sa.7, 2022 (SCI-Expanded, Scopus)

2022

85. 971TiP Phase III trial of durvalumab combined with domvanalimab following concurrent chemoradiotherapy (cCRT) in patients with unresectable stage III NSCLC (PACIFIC-8)

Ozguroglu M., Levy B., Horinouchi H., Yu J., Grainger E., Phuong P., et al.

ANNALS OF ONCOLOGY , cilt.33, ss.1, 2022 (SCI-Expanded, Scopus)

2022

86. Genomic aberrations associated with overall survival (OS) in metastatic castration-sensitive prostate cancer (mCSPC) treated with apalutamide (APA) or placebo (PBO) plus androgen deprivation therapy (ADT) in TITAN.

Agarwal N., Lucas J., Aguilar-Bonavides C., Thomas S., Gormley M., Chowdhury S., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.40, sa.16, 2022 (SCI-Expanded, Scopus)

2022

87. Tolerability of abiraterone (abi) combined with olaparib (ola) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Further results from the phase III PROpel trial.

Thiery-Vuillemin A., Saad F., Armstrong A. J., Oya M., Vianna K. C. M., Ozguroglu M., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.40, sa.16, 2022 (SCI-Expanded, Scopus)

2022

88. Olaparib tolerability and common adverse-event management in patients with metastatic castration-resistant prostate cancer: Further analyses from the PROfound study.

Roubaud G., Özgüroğlu M., Penel N., Matsubara N., Mehra N., Kolinsky M. P., et al.

European journal of cancer (Oxford, England : 1990) , cilt.170, ss.73-84, 2022 (SCI-Expanded, Scopus)

2022

89. Efficacy and safety of trifluridine/tipiracil in older and younger patients with metastatic gastric or gastroesophageal junction cancer: subgroup analysis of a randomized phase 3 study (TAGS).

Shitara K., Doi T., Hosaka H., Thuss-Patience P., Santoro A., Longo F., et al.

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association , cilt.25, ss.586-597, 2022 (SCI-Expanded, Scopus)

2022

90. Durvalumab

Bischoff H., Paz-Ares L., Chen Y., Reinmuth N., Hotta K., Trukhin D., et al.

PNEUMOLOGIE , cilt.76, 2022 (ESCI, Scopus)

2022

91. Impact of Brain Metastases on Treatment Patterns and Outcomes With First-Line Durvalumab Plus Platinum-Etoposide in Extensive-Stage SCLC (CASPIAN): A Brief Report.

Chen Y., Paz-Ares L., Reinmuth N., Garassino M. C., Statsenko G., Hochmair M. J., et al.

JTO clinical and research reports , cilt.3, sa.6, ss.100330, 2022 (ESCI)

2022

92. Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib).

Hussain M., Corcoran C., Sibilla C., Fizazi K., Saad F., Shore N., et al.

Clinical cancer research : an official journal of the American Association for Cancer Research , cilt.28, sa.8, ss.1518-1530, 2022 (SCI-Expanded, Scopus)

2022

93. Comparison of iodine-125 plaque brachytherapy and gamma knife stereotactic radiosurgery treatment outcomes for uveal melanoma patients.

Guleser U. Y., Sarici A. M., Ucar D., Gonen B., Sengul Samanci N., Özgüroğlu M.

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie , cilt.260, sa.4, ss.1337-1343, 2022 (SCI-Expanded, Scopus)

2022

94. Patient-reported outcomes (PROs) with first-line (1L) cemiplimab in patients with locally advanced non-small cell lung cancer (laNSCLC): EMPOWER-Lung 1 subpopulation

Bondarenko I., Sezer A., Kilickap S., GÜMÜŞ M., Ozguroglu M., Gogishvili M., et al.

ANNALS OF ONCOLOGY , cilt.33, 2022 (SCI-Expanded, Scopus)

2022

95. Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.

Spigel D. R., Faivre-Finn C., Gray J. E., Vicente D., Planchard D., Paz-Ares L., et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology , cilt.40, ss.1301-1324, 2022 (SCI-Expanded, Scopus)

2022

96. Durvalumab (D) +/- tremelimumab (T) plus platinum-etoposide (EP) in 1L extensive-stage (ES) SCLC: Characteristics of long-term survivors in the CASPIAN study

Reinmuth N., Goldman J. W., Garassino M. C., Chen Y., Hotta K., Poltoratskiy A., et al.

ANNALS OF ONCOLOGY , cilt.33, 2022 (SCI-Expanded, Scopus)

2022

97. Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN.

Paz-Ares L., Chen Y., Reinmuth N., Hotta K., Trukhin D., Statsenko G., et al.

ESMO open , cilt.7, sa.2, ss.100408, 2022 (SCI-Expanded, Scopus)

2022

98. Outcomes with durvalumab after chemoradiotherapy in stage IIIA-N2 non-small-cell lung cancer: an exploratory analysis from the PACIFIC trial.

Senan S., Özgüroğlu M., Daniel D., Villegas A., Vicente D., Murakami S., et al.

ESMO open , cilt.7, sa.2, ss.100410, 2022 (SCI-Expanded, Scopus)

2022

99. Evaluating Alternative Ramucirumab Doses as a Single Agent or with Paclitaxel in Second-Line Treatment of Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma: Results from Two Randomized, Open-Label, Phase II Studies.

Shah M. A., Udrea A. A., Bondarenko I., Mansoor W., Sánchez R. G., Sarosiek T., et al.

Cancers , cilt.14, sa.5, 2022 (SCI-Expanded, Scopus)

2022

100. Characterizing immune-mediated adverse events with durvalumab in patients with unresectable stage III NSCLC: A post-hoc analysis of the PACIFIC trial.

Naidoo J., Vansteenkiste J. F., Faivre-Finn C., Özgüroğlu M., Murakami S., Hui R., et al.

Lung cancer (Amsterdam, Netherlands) , cilt.166, ss.84-93, 2022 (SCI-Expanded, Scopus)

2022

101. Phase II study of afatinib plus pembrolizumab in patients with squamous cell carcinoma of the lung following progression during or after first-line chemotherapy (LUX-Lung-IO).

Levy B., Barlesi F., Paz-Ares L., Bennouna J., Erman M., Felip E., et al.

Lung cancer (Amsterdam, Netherlands) , cilt.166, ss.107-113, 2022 (SCI-Expanded, Scopus)

2022

102. First-line pembrolizumab in advanced urothelial carcinoma: Clinical parameters associated with efficacy in the phase 2 KEYNOTE-052 and phase 3 KEYNOTE-361 trials.

Csoszi T., Powles T., Alva A. S., Castellano D. E., Ozguroglu M., O'donnell P. H., et al.

Journal Of Clinical Oncology , cilt.40, sa.6_suppl, 2022 (SCI-Expanded, Scopus)

2022

103. Association of TMB and PD-L1 with efficacy of first-line pembrolizumab (pembro) or pembro + chemotherapy (chemo) versus chemo in patients (pts) with advanced urothelial carcinoma (UC) from KEYNOTE-361.

Morales-Barrera R., Powles T., Ozguroglu M., Csoszi T., Loriot Y., Flechon A., et al.

Journal Of Clinical Oncology , cilt.40, sa.6_suppl, 2022 (SCI-Expanded, Scopus)

2022

104. The Impact of Hybrid Capture-Based Comprehensive Genomic Profiling on Treatment Strategies in Patients with Solid Tumors

Dişel U., Köse F., Bilici A., ÖZGÜROĞLU M., Sağlam S., ŞEKER M., et al.

Journal of Oncological Science , cilt.8, sa.2, ss.87-93, 2022 (Scopus, TRDizin)

2022

105. Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial.

Fuchs C. S., Özgüroğlu M., Bang Y., Di Bartolomeo M., Mandala M., Ryu M., et al.

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association , cilt.25, sa.1, ss.197-206, 2022 (SCI-Expanded, Scopus)

2022

106. A Randomized Phase II Study of Anti-CSF-1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple Negative Breast Cancer.

Kuemmel S., Campone M., Loirat D., López López R., Beck J. T., De Laurentiis M., et al.

Clinical cancer research : an official journal of the American Association for Cancer Research , cilt.28, ss.106-115, 2022 (SCI-Expanded, Scopus)

2021

107. An Open-Label, Multinational, Multicenter, Phase IIIb Study with Subcutaneous Administration of Trastuzumab in Patients with HER2-Positive Early Breast Cancer to Evaluate Patient Satisfaction.

Cicin İ., Oukkal M., Mahfouf H., Mezlini A., Larbaoui B., Ahmed S. B., et al.

European journal of breast health , cilt.18, sa.1, ss.63-73, 2021 (ESCI, Scopus, TRDizin)

2021

108. Impact of abiraterone acetate plus prednisone in patients with castration-sensitive prostate cancer and visceral metastases over four years of follow-up: A post-hoc exploratory analysis of the LATITUDE study.

Baciarello G., Özgüroğlu M., Mundle S., Leitz G., Richarz U., Hu P., et al.

European journal of cancer (Oxford, England : 1990) , cilt.162, ss.56-64, 2021 (SCI-Expanded, Scopus)

2021

109. A Phase II Trial of Prexasertib (LY2606368) in Patients With Extensive-Stage Small-Cell Lung Cancer.

Byers L. A., Navarro A., Schaefer E., Johnson M., Özgüroğlu M., Han J., et al.

Clinical lung cancer , cilt.22, ss.531-540, 2021 (SCI-Expanded, Scopus)

2021

110. Durvalumab After Concurrent Chemoradiotherapy in Elderly Patients With Unresectable Stage III Non-Small-Cell Lung Cancer (PACIFIC).

Socinski M. A., Özgüroğlu M., Villegas A., Daniel D., Vicente D., Murakami S., et al.

Clinical lung cancer , cilt.22, ss.549-561, 2021 (SCI-Expanded, Scopus)

2021

111. Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061

Van Cutsem E., Amonkar M., Fuchs C. S., Alsina M., ÖZGÜROĞLU M., Bang Y., et al.

GASTRIC CANCER , cilt.24, sa.6, ss.1330-1340, 2021 (SCI-Expanded, Scopus)

2021

112. Reply by Authors.

Agarwal N., McQuarrie K., Bjartell A., Chowdhury S., Pereira de Santana Gomes A. J., Chung B. H., et al.

The Journal of urology , cilt.206, ss.914-922, 2021 (SCI-Expanded, Scopus)

2021

113. Apalutamide Plus Androgen Deprivation Therapy for Metastatic Castration-Sensitive Prostate Cancer: Analysis of Pain and Fatigue in the Phase 3 TITAN Study.

Agarwal N., McQuarrie K., Bjartell A., Chowdhury S., Pereira de Santana Gomes A. J., Chung B. H., et al.

The Journal of urology , cilt.206, ss.914-923, 2021 (SCI-Expanded, Scopus)

2021

114. Clinical Benefit of First-Line Cemiplimab in Patients with Locally Advanced NSCLC: Subgroup Analysis from EMPOWER-Lung 1

Bondarenko I., Sezer A., KILIÇKAP S., GÜMÜŞ M., Ozguroglu M., Gogishvili M., et al.

JOURNAL OF THORACIC ONCOLOGY , cilt.16, sa.10, 2021 (SCI-Expanded, Scopus)

2021

115. 5-year survival outcomes with durvalumab after chemoradiotherapy in unresectable Stage III NSCLC - an update from the PACIFIC trial

de Wit M., Spigel D. R., Faivre-Finn C., Gray J. E., Vicente D., Planchard D., et al.

ONCOLOGY RESEARCH AND TREATMENT , cilt.44, ss.109-110, 2021 (SCI-Expanded, Scopus)

2021

116. Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase 3 trial in patients with gastroesophageal adenocarcinoma.

Shitara K., Özgüroğlu M., Bang Y., Di Bartolomeo M., Mandalà M., Ryu M., et al.

Annals of oncology : official journal of the European Society for Medical Oncology , cilt.32, ss.1127-1136, 2021 (SCI-Expanded, Scopus)

2021

117. Avelumab vs docetaxel in patients with platinum-treated advanced non-small-cell lung cancer: 2-year follow-up from the JAVELIN Lung 200 phase 3 trial.

Park K., Özgüroğlu M., Vansteenkiste J., Spigel D., Yang J. C., Ishii H., et al.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer , cilt.16, ss.1369-1378, 2021 (SCI-Expanded, Scopus)

2021

118. Nivolumab in metastatic renal cell carcinoma: results from the Turkish Oncology Group Kidney Cancer Consortium database.

Yekedüz E., Ertürk İ., Tural D., Karadurmuş N., Karakaya S., Hızal M., et al.

Future oncology (London, England) , cilt.17, ss.4861-4869, 2021 (SCI-Expanded, Scopus)

2021

119. Immune-related adverse events associated with immune checkpoint inhibitors in patients with cancer

Sengul S., Cikman D., Oruc K., Bedir S., Çelik E., Degerli E., et al.

TUMORI J , cilt.107, sa.4, ss.304-310, 2021 (SCI-Expanded, Scopus)

2021

120. Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study.

Chi K. N., Chowdhury S., Bjartell A., Chung B. H., Pereira de Santana Gomes A. J., Given R., et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology , cilt.39, ss.2294-2304, 2021 (SCI-Expanded, Scopus)

2021

121. Durvalumab(D) +/- tremelimumab(T) plus platinum-etoposide(EP) in 1L ES-SCLC: Characterization of long-term benefit in CASPIAN

Saito H., Goldman J. W., Garassino M. C., Chen Y., Reinmuth N., Hotta K., et al.

ANNALS OF ONCOLOGY , cilt.32, 2021 (SCI-Expanded, Scopus)

2021

122. Osimertinib Maintenance After Definitive Chemoradiation in Patients With Unresectable EGFR Mutation Positive Stage III Non-small-cell Lung Cancer: LAURA Trial in Progress.

Lu S., Casarini I., Kato T., Cobo M., Özgüroğlu M., Hodge R., et al.

Clinical lung cancer , cilt.22, ss.371-375, 2021 (SCI-Expanded, Scopus)

2021

123. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial.

Powles T., Csőszi T., Özgüroğlu M., Matsubara N., Géczi L., Cheng S. Y., et al.

The Lancet. Oncology , cilt.22, ss.931-945, 2021 (SCI-Expanded, Scopus)

2021

124. 5-Year Survival Data of Durvalumab after Chemoradiotherapy for unresectable Stage III NSCLC - an Update from the PACIFIC Study

de Wit M., Spigel D., Faivre-Finn C., Gray J., Vicente D., Planchard D., et al.

STRAHLENTHERAPIE UND ONKOLOGIE , cilt.197, 2021 (SCI-Expanded, Scopus)

2021

125. Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability-High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials.

Chao J., Fuchs C. S., Shitara K., Tabernero J., Muro K., Van Cutsem E., et al.

JAMA oncology , cilt.7, ss.895-902, 2021 (SCI-Expanded, Scopus)

2021

126. Apalutamide (apa) for metastatic castration-sensitive prostate cancer (mcspc): Outcomes in high-volume (hv) and low-volume (lv) disease from the titan final analysis (fa)

Chowdhury S., Bjartell A., Merseburger A. S., Chung B. H., Uemura H., Ye D., et al.

EUROPEAN UROLOGY , cilt.79, 2021 (SCI-Expanded, Scopus)

2021

127. Cemiplimab monotherapy as first-line (1L) treatment of patients with brain metastases from advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) >= 50%: EMPOWER-Lung 1 subgroup analysis.

Ozguroglu M., Sezer A., Kilickap S., Gumus M., Bondarenko I., Gogishvili M., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.39, sa.15, 2021 (SCI-Expanded, Scopus)

2021

128. Brief report: Four-year survival with durvalumab after chemoradiotherapy in Stage III NSCLC - an update from the PACIFIC trial.

Faivre-Finn C., Vicente D., Kurata T., Planchard D., Paz-Ares L., Vansteenkiste J. F., et al.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer , cilt.16, ss.860-867, 2021 (SCI-Expanded, Scopus)

2021

129. A challenging task - Identifying patients with cancer of unknown primary (CUP) according to ESMO guidelines: the CUPISCO trial experience.

Pauli C., Bochtler T., Mileshkin L., Baciarello G., Losa F., Ross J. S., et al.

The oncologist , cilt.26, 2021 (SCI-Expanded, Scopus)

2021

130. Health-related quality of life (HRQoL) and patient-reported outcomes at final analysis of the TITAN study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT).

Agarwal N., Chowdhury S., Bjartell A., Chung B. H., Gomes A. J. P. d. S., Given R., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.39, sa.15, 2021 (SCI-Expanded, Scopus)

2021

131. Patient-reported symptoms, functioning, and quality of life (QoL) in patients treated with cemiplimab monotherapy for first-line treatment of advanced NSCLC with PD-L1 >= 50%: Results from EMPOWER-Lung 1 study.

Gumus M., Chen C., Ivanescu C., Kilickap S., Bondarenko I., Ozguroglu M., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.39, sa.15, 2021 (SCI-Expanded, Scopus)

2021

132. Five-year survival outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC: An update from the PACIFIC trial.

Spigel D. R., Faivre-Finn C., Gray J. E., Vicente D., Planchard D., Paz-Ares L. G., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.39, sa.15, 2021 (SCI-Expanded, Scopus)

2021

133. Radium-223 (Ra-223) versus novel antihormone therapy (NAH) for progressive metastatic castration-resistant prostate cancer (mCRPC) after 1 line of NAH: RADIANT, an international phase 4, randomized, open-label study.

Fizazi K., Gonzalez del Alba A., Mustafa O., Skoneczna I. A., Krissel H., Uema D., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.39, sa.15, 2021 (SCI-Expanded, Scopus)

2021

134. First-line Treatment with Durvalumab and Platinum-Etoposide Combination for Patients with ED-SCLC: Exploratory Analyzes based on the Disease Extent in CASPIAN

Bischoff H., Reinmuth N., Dvorkin M., Garassino M. C., Trukhin D., Hochmair M. J., et al.

PNEUMOLOGIE , cilt.75, 2021 (ESCI, Scopus)

2021

135. Patient-reported outcomes with durvalumab by PD-L1 expression and prior chemoradiotherapy-related variables in unresectable, stage III non-small-cell lung cancer.

Garassino M. C., Paz-Ares L., Hui R., Faivre-Finn C., Spira A., Planchard D., et al.

Future oncology (London, England) , cilt.17, ss.1165-1184, 2021 (SCI-Expanded, Scopus)

2021

136. Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100.

Moehler M., Dvorkin M., Boku N., Özgüroğlu M., Ryu M., Muntean A., et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology , cilt.39, 2021 (SCI-Expanded, Scopus)

2021

137. Population Pharmacokinetics and Exposure-Response with Durvalumab Plus Platinum-Etoposide in ES-SCLC: Results from CASPIAN

Zheng Y., Jin D., Guan Y., Ozguroglu M., Trukhin D., Poltoratskiy A., et al.

JOURNAL OF THORACIC ONCOLOGY , cilt.16, sa.3, 2021 (SCI-Expanded, Scopus)

2021

138. First-Line Durvalumab plus Platinum-Etoposide in ES-SCLC: Exploratory Analyses Based on Extent of Disease in CASPIAN

Reinmuth N., Garassino M. C., Trukhin D., Hochmair M. J., Ozguroglu M., Havel L., et al.

JOURNAL OF THORACIC ONCOLOGY , cilt.16, sa.3, 2021 (SCI-Expanded, Scopus)

2021

139. Clinical Benefits of First-Line (1L) Cemiplimab Monotherapy by PD-L1 Expression Levels in Patients With Advanced NSCLC

KILIÇKAP S., Sezer A., GÜMÜŞ M., Bondarenko I., Ozguroglu M., Gogishvili M., et al.

JOURNAL OF THORACIC ONCOLOGY , cilt.16, sa.3, 2021 (SCI-Expanded, Scopus)

2021

140. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial.

Sezer A., Kilickap S., Gümüş M., Bondarenko I., Özgüroğlu M., Gogishvili M., et al.

Lancet (London, England) , cilt.397, ss.592-604, 2021 (SCI-Expanded, Scopus)

2021

141. Impact of subsequent immune checkpoint inhibitor treatment on overall survival with avelumab vs docetaxel in platinum-treated advanced NSCLC: Post hoc analyses from the phase 3 JAVELIN Lung 200 trial.

Park K., Özgüroğlu M., Vansteenkiste J., Spigel D., Yang J. C., Bajars M., et al.

Lung cancer (Amsterdam, Netherlands) , cilt.154, ss.92-98, 2021 (SCI-Expanded, Scopus)

2021

142. Post-hoc analysis of long-term outcomes in patients with CR, PR, or SD to pembrolizumab (pembro) or platinum-based chemotherapy (chemo) as 1L therapy for advanced urothelial carcinoma (UC) in KEYNOTE-361.

Loriot Y., Alva A. S., Csoszi T., ÖZGÜROĞLU M., Matsubara N., Geczi L., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.39, sa.6, 2021 (SCI-Expanded, Scopus)

2021

143. Impact of subsequent therapy on survival in KEYNOTE-361: Pembrolizumab (pembro) plus chemotherapy (chemo) or pembro alone versus chemo as first-line therapy for advanced urothelial carcinoma (UC).

Alva A. S., Csoszi T., ÖZGÜROĞLU M., Matsubara N., Geczi L., Cheng S. Y., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.39, sa.6, 2021 (SCI-Expanded, Scopus)

2021

144. Final analysis results from TITAN: A phase III study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT).

Chi K. N., Chowdhury S., Bjartell A., Chung B. H., de Santana Gomes A. J. P., Given R., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.39, sa.6, 2021 (SCI-Expanded, Scopus)

2021

145. Analysis of PFS2 by subsequent therapy in KEYNOTE-361: Pembrolizumab (pembro) plus chemotherapy (chemo) or pembro alone versus chemo as 1L therapy for advanced urothelial carcinoma (UC).

ÖZGÜROĞLU M., Alva A. S., Csoszi T., Matsubara N., Geczi L., Cheng S. Y., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.39, sa.6, 2021 (SCI-Expanded, Scopus)

2021

146. 1L pembrolizumab (pembro) versus chemotherapy (chemo) for choice-of-carboplatin patients with advanced urothelial carcinoma (UC) in KEYNOTE-361.

Powles T., Csoszi T., ÖZGÜROĞLU M., Matsubara N., Geczi L., Cheng S. Y., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.39, sa.6, 2021 (SCI-Expanded, Scopus)

2021

147. Nivolumab as second-line treatment and beyond for metastatic renal cell carcinoma: A real-life experience from Turkish Oncology Group Kidney Cancer Consortium (TKCC) Database.

Yekeduz E., Erturk I., Tural D., Karadurmus N., Karakaya S., Hizal M., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.39, sa.6, 2021 (SCI-Expanded, Scopus)

2021

148. The relationship between eGFR and capecitabine efficacy/toxicity in metastatic breast cancer.

Celik E., Samanci N. S., Karadag M., Demirci N. S., Demirelli F. H., Ozguroglu M.

Medical oncology (Northwood, London, England) , cilt.38, ss.11, 2021 (SCI-Expanded, Scopus)

2021

149. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.

Goldman J., Dvorkin M., Chen Y., Reinmuth N., Hotta K., Trukhin D., et al.

The Lancet. Oncology , cilt.22, ss.51-65, 2021 (SCI-Expanded, ESCI, Scopus)

2021

150. Durvalumab +/- tremelimumab plus platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): 3-year overall survival update from the phase III CASPIAN study

Paz-Ares L., Chen Y., Reinmuth N., Hotta K., Trukhin D., Statsenko G., et al.

ANNALS OF ONCOLOGY , cilt.32, 2021 (SCI-Expanded, Scopus)

2020

151. Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer.

Hussain M., Mateo J., Fizazi K., Saad F., Shore N., Sandhu S., et al.

The New England journal of medicine , cilt.383, ss.2345-2357, 2020 (SCI-Expanded, Scopus)

2020

152. Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC).

Faivre-Finn C., Spigel D., Senan S., Langer C., Perez B., Özgüroğlu M., et al.

Lung cancer (Amsterdam, Netherlands) , cilt.151, ss.30-38, 2020 (SCI-Expanded, Scopus)

2020

153. Clinical efficacy of atezolizumab (atezo) in biomarker subgroups by PD-L1 immunohistochemistry (IHC) assays and blood tumour mutational burden (bTMB): IMpower110

Herbst R. S., De Marinis F., Giaccone G., Stahel R., Reinmuth N., Vergnenegre A., et al.

SWISS MEDICAL WEEKLY , 2020 (SCI-Expanded, Scopus)

2020

154. Final overall survival analysis of PROfound: olaparib vs physician's choice of enzalutamide or abiraterone in patients with metastatic castration resistant prostate cancer and homologous recombination repair (HRR) gene alterations.

Sandhu S., de Bono J., Mateo J., Fizazi K., Fred S., Shore N., et al.

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY , cilt.16, ss.41, 2020 (SCI-Expanded, Scopus)

2020

155. Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC.

Herbst R., Giaccone G., de M., Reinmuth N., Vergnenegre A., Barrios C., et al.

The New England journal of medicine , cilt.383, ss.1328-1339, 2020 (SCI-Expanded, Scopus)

2020

156. First-line durvalumab plus platinum-etoposide in extensive-stage (ES)-SCLC (CASPIAN): Impact of brain metastases on treatment patterns and outcomes

Schulz C., Chen Y., Paz-Ares L. G., Dvorkin M., Trukhin D., Reinmuth N., et al.

ONCOLOGY RESEARCH AND TREATMENT , cilt.43, ss.144-145, 2020 (SCI-Expanded, Scopus)

2020

157. Durvalumab +/- tremelimumab plus platinum-etoposide in first-line (1L) extensive-stage SCLC (ES-SCLC): Results from the phase 3 CASPIAN study

Grohe C., Paz-Ares L. G., Dvorkin M., Chen Y., Hotta K., Trukhin D., et al.

ONCOLOGY RESEARCH AND TREATMENT , cilt.43, ss.149, 2020 (SCI-Expanded, Scopus)

2020

158. Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase III study.

Goldman J., Garassino M., Chen Y., Özgüroğlu M., Dvorkin M., Trukhin D., et al.

Lung cancer (Amsterdam, Netherlands) , cilt.149, ss.46-52, 2020 (SCI-Expanded, Scopus)

2020

159. PIVOT-10: Phase II study of bempegaldesleukin plus nivolumab in cisplatin-ineligible advanced urothelial cancer.

Huddart R., Siefker-Radtke A., Balar A., Bilen M., Powles T., Bamias A., et al.

Future oncology (London, England) , cilt.17, ss.137-149, 2020 (SCI-Expanded, Scopus)

2020

160. Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial

Paz-Ares L., Spira A., Raben D., Planchard D., Cho B. C., Ozguroglu M., et al.

ANNALS OF ONCOLOGY , cilt.31, sa.6, ss.798-806, 2020 (SCI-Expanded, Scopus)

2020

161. First-line durvalumab plus platinum-etoposide in extensive-stage (ES)-SCLC (CASPIAN): Impact of brain metastases on treatment patterns and outcomes.

Chen Y., Paz-Ares L. G., Dvorkin M., Trukhin D., Reinmuth N., Chiara Garassino M., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.38, sa.15, 2020 (SCI-Expanded, Scopus)

2020

162. The association of tissue tumor mutational burden (tTMB) using the Foundation Medicine genomic platform with efficacy of pembrolizumab versus paclitaxel in patients (pts) with gastric cancer (GC) from KEYNOTE-061.

Shitara K., Ozguroglu M., Bang Y., Di Bartolomeo M., Mandal M., Ryu M., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.38, sa.15, 2020 (SCI-Expanded, Scopus)

2020

163. Pembrolizumab versus paclitaxel for previously treated patients with PD-L1-positive advanced gastric or gastroesophageal junction cancer (GC): Update from the phase III KEYNOTE-061 trial.

Fuchs C. S., Ozguroglu M., Bang Y., Di Bartolomeo M., Mandala M., Ryu M., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.38, sa.15, 2020 (SCI-Expanded, Scopus)

2020

164. The association of molecular biomarkers with efficacy of pembrolizumab versus paclitaxel in patients with gastric cancer (GC) from KEYNOTE-061.

Fuchs C. S., Ozguroglu M., Bang Y., Di Bartolomeo M., Mandala M., Ryu M., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.38, sa.15, 2020 (SCI-Expanded, Scopus)

2020

165. Non-pneumonitis immune-mediated adverse events (imAEs) with durvalumab in patients with unresectable stage III NSCLC (PACIFIC).

Naidoo J., Vansteenkiste J. F., Faivre-Finn C., Ozguroglu M., Murakami S., Hui R., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.38, sa.15, 2020 (SCI-Expanded, Scopus)

2020

166. Determine the impact of hybrid capture-based comprehensive genomic profiling (CGP) on the treatment strategies in patients with solid tumors: A national, multicenter, retrospective study.

Disel U., Kose F., Bilici A., Ozguroglu M., Saglam S., Seker M., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.38, sa.15, 2020 (SCI-Expanded, Scopus)

2020

167. Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial

Galsky M. D., Arranz Arija J. A., Bamias A., Davis I. D., De Santis M., Kikuchi E., et al.

LANCET , cilt.395, sa.10236, ss.1547-1557, 2020 (SCI-Expanded, Scopus)

2020

168. Durvalumab +/- tremelimumab plus platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): Updated results from the phase III CASPIAN study.

Paz-Ares L. G., Dvorkin M., Chen Y., Reinmuth N., Hotta K., Trukhin D., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.38, sa.15, 2020 (SCI-Expanded, Scopus)

2020

169. IMPOWER110: INTERIM OVERALL SURVIVAL (OS) ANALYSIS OF A PHASE III STUDY OF ATEZOLIZUMAB (ATEZO) MONOTHERAPY VS PLATINUM-BASED CHEMOTHERAPY (CHEMO) AS FIRST-LINE (1L) TREATMENT IN PD-L1-SELECTED NSCLC

Herbst R., De Marinis F., Giaccone G., Reinmuth N., Vergnenegre A., Barrios C., et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER , cilt.8, 2020 (SCI-Expanded, Scopus)

2020

170. Correlation of Prostate-specific Antigen Kinetics with Overall Survival and Radiological Progression-free Survival in Metastatic Castration-sensitive Prostate Cancer Treated with Abiraterone Acetate plus Prednisone or Placebos Added to Androgen Deprivation Therapy: Post Hoc Analysis of Phase 3 LATITUDE Study.

Matsubara N., Chi K., Özgüroğlu M., Rodriguez-Antolin A., Feyerabend S., Fein L., et al.

European urology , cilt.77, ss.494-500, 2020 (SCI-Expanded, Scopus)

2020

171. CASPIAN: OS results from a randomised Phase III study of first-line Durvalumab +/- Tremelimumab plus chemotherapy in ED-SCLC: OS-Ergebnisse von CASPIAN, einer randomisierten Phase-III-Studie zur Erstlinientherapie von Durvalumab +/- Tremelimumab

Reinmuth N., Paz-Ares L., Chen Y., Hotta K., Trukhin D., Statsenko G., et al.

PNEUMOLOGIE , cilt.74, 2020 (ESCI, Scopus)

2020

172. PROfound: Efficacy of olaparib (ola) by prior taxane use in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations.

De Bono J. S., Fizazi K., Saad F., Shore N. D., Roubaud G., Ozguroglu M., et al.

Journal of Clinical Oncology , cilt.38, sa.6_suppl, ss.134, 2020 (SCI-Expanded, Scopus)

2020

173. Time to second progression (PFS2) in patients (pts) from TITAN with metastatic castration-sensitive prostate cancer (mCSPC) by first subsequent therapy (hormonal vs. taxane).

Agarwal N., Chowdhury S., Bjartell A., Chung B. H., Pereira de Santana Gomes A. J., Given R. W., et al.

Journal of Clinical Oncology , cilt.38, sa.6_suppl, ss.82, 2020 (SCI-Expanded, Scopus)

2020

174. PIVOT-10: A phase II study of bempegaldesleukin (NKTR-214) in combination with nivolumab (NIVO) in cisplatin (cis) ineligible patients with previously untreated locally advanced or metastatic urothelial cancer (mUC).

Huddart R. A., Siefker-Radtke A. O., Balar A. V., Bilen M. A., Powles T., Bamias A., et al.

Journal of Clinical Oncology , cilt.38, sa.6_suppl, 2020 (SCI-Expanded, Scopus)

2020

175. Apalutamide (APA) for metastatic castration-sensitive prostate cancer (mCSPC) in TITAN: Outcomes in patients (pts) with low- and high-risk disease.

Ozguroglu M., Chowdhury S., Bjartell A., Uemura H., Chung B. H., Agarwal N., et al.

Journal of Clinical Oncology , cilt.38, sa.6_suppl, ss.87, 2020 (SCI-Expanded, Scopus)

2020

176. Results of the JAVELIN Gastric 100 phase 3 trial: avelumab maintenance following first-line (1L) chemotherapy (CTx) vs continuation of CTx for HER2− advanced gastric or gastroesophageal junction cancer (GC/GEJC).

Moehler M. H., Dvorkin M., Ozguroglu M., Ryu M., Muntean A. S., Lonardi S., et al.

Journal of Clinical Oncology , cilt.38, sa.4_suppl, ss.278, 2020 (SCI-Expanded, Scopus)

2020

177. Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC-Update from PACIFIC

Gray J. E., Villegas A., Daniel D., Vicente D., Murakami S., Hui R., et al.

JOURNAL OF THORACIC ONCOLOGY , cilt.15, sa.2, ss.288-293, 2020 (SCI-Expanded, Scopus)

2020

178. Central, Prospective Detection of Homologous Recombination Repair (HRR) Gene Alteration in Tumor Tissue From > 4000 Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Screened for The Profound Study

Stenzl A., Hussain M., Fizazi K., Saad F., Shore N., Sandhu S., et al.

ONCOLOGY RESEARCH AND TREATMENT , cilt.43, ss.81, 2020 (SCI-Expanded, Scopus)

2020

179. First Subsequent Treatment After Discontinuation of Durvalumab in Unresectable, Stage III NSCLC Patients from PACIFIC

Faehling M., Planchard D., Cho B. C., Gray J. E., Paz-Ares L. G., Ozguroglu M., et al.

ONCOLOGY RESEARCH AND TREATMENT , cilt.43, ss.120, 2020 (SCI-Expanded, Scopus)

2020

180. Pembrolizumab (pembro) in microsatellite instability-high (MSI-H) advanced gastric/gastroesophageal junction (G/GEJ) cancer by line of therapy.

Chao J., Fuchs C. S., Shitara K., Tabernero J., Muro K., Van Cutsem E., et al.

Journal of Clinical Oncology , cilt.38, sa.4_suppl, ss.430, 2020 (SCI-Expanded, Scopus)

2020

181. Caspian: Os Results from a Randomised Phase 3 Study of First-Line Durvalumab +/- Tremelimumab plus Chemotherapy in ES-SCLC

Reinmuth N., Paz-Ares L., Chen Y., Hotta K., Trukhin D., Statsenko G., et al.

ONCOLOGY RESEARCH AND TREATMENT , cilt.43, ss.115, 2020 (SCI-Expanded, Scopus)

2020

182. Apalutamide (APA) for metastatic castration-sensitive prostate cancer (mCSPC) in TITAN: Outcomes in patients (pts) with de novo (D1) mCSPC vs. progression to mCSPC after localized disease (D0) at diagnosis

Özgüroğlu M.

European Urology Open Science , cilt.19, ss.1, 2020 (Düzenli olarak gerçekleştirilen hakemli kongrenin bildiri kitabı)

2020

183. 379MO Durvalumab (D)$±$tremelimumab (T)+ platinum-etoposide (EP) in 1L ES-SCLC: Characterization of long-term clinical benefit and tumour mutational burden (TMB) in CASPIAN

Özgüroğlu M.

Annals of Oncology , cilt.31, ss.1388-1389, 2020 (Düzenli olarak gerçekleştirilen hakemli kongrenin bildiri kitabı)

2019

184. Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study

Hui R., ÖZGÜROĞLU M., Villegas A., Daniel D., Vicente D., Murakami S., et al.

LANCET ONCOLOGY , cilt.20, sa.12, ss.1670-1680, 2019 (SCI-Expanded, Scopus)

2019

185. LBA1 Clinical efficacy of atezolizumab (atezo) in biomarker subgroups by SP142, SP263 and 22C3 PD-L1 immunohistochemistry (IHC) assays and by blood tumour mutational burden (bTMB): Results from the IMpower110 study

Herbst R., de Marinis F., Giaccone G., Reinmuth N., Vergnenegre A., Barrios C., et al.

Annals of Oncology , cilt.30, 2019 (SCI-Expanded, Scopus)

2019

186. Immune-related adverse events associated with immune-checkpoint inhibitors: A single center experience

Samanci N., Oruc K., Bedir S., Celik E., Degerli E., Derin S., et al.

Annals of Oncology , cilt.30, 2019 (SCI-Expanded, Scopus)

2019

187. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.

PAZ-ARES L., DVORKIN M., CHEN Y., REINMUTH N., HOTTA K., TRUKHIN D., et al.

Lancet (London, England) , cilt.394, ss.1929-1939, 2019 (SCI-Expanded, Scopus)

2019

188. 2-year follow-up from JAVELIN Lung 200, an open-label, randomized, phase 3 study of avelumab vs docetaxel in patients with platinum-treated advanced non-small cell lung cancer (NSCLC)

Barlesi F., Ozguroglu M., Vansteenkiste J., Spigel D., Yang J., Ishii H., et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER , cilt.7, 2019 (SCI-Expanded, Scopus)

2019

189. Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study.

AGARWAL N., MCQUARRIE K., BJARTELL A., CHOWDHURY S., PEREIRA D. S. G. A., CHUNG B., et al.

The Lancet. Oncology , cilt.20, ss.1518-1530, 2019 (SCI-Expanded, Scopus)

2019

190. Overall Survival with Durvalumab Plus Etoposide-Platinum in First-Line Extensive-Stage SCLC: Results from the CASPIAN Study

Paz-Ares L., Chen Y., Reinmuth N., Hotta K., Trukhin D., Statsenko G., et al.

JOURNAL OF THORACIC ONCOLOGY , cilt.14, sa.10, 2019 (SCI-Expanded, Scopus)

2019

191. Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer.

CHI K., AGARWAL N., BJARTELL A., CHUNG B., PEREIRA D. S. G. A., GIVEN R., et al.

The New England journal of medicine , cilt.381, ss.13-24, 2019 (SCI-Expanded, Scopus)

2019

192. Three-year overall survival update from the PACIFIC trial.

Gray J. E., Villegas A. E., Daniel D. B., Vicente D., Murakami S., Hui R., et al.

Journal of Clinical Oncology , cilt.37, sa.15_suppl, 2019 (SCI-Expanded, Scopus)

2019

193. Afatinib With Pembrolizumab for Treatment of Patients With Locally Advanced/Metastatic Squamous Cell Carcinoma of the Lung: The LUX-Lung IO/KEYNOTE 497 Study Protocol.

LEVY B., PAZ-ARES L., BENNOUNA J., FELIP E., ABREU D., ISLA D., et al.

Clinical lung cancer , cilt.20, 2019 (SCI-Expanded, Scopus)

2019

194. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial.

FIZAZI K., TRAN N., FEIN L., MATSUBARA N., RODRIGUEZ-ANTOLIN A., ALEKSEEV B., et al.

The Lancet. Oncology , cilt.20, ss.686-700, 2019 (SCI-Expanded, Scopus)

2019

195. Patient-reported outcomes (PROs) with durvalumab by PD-L1 expression in unresectable, stage III NSCLC (PACIFIC)

Garassino M., Paz-Ares L., Hui R., Faivre-Finn C., Spira A., Planchard D., et al.

Annals of Oncology , cilt.30, 2019 (SCI-Expanded, Scopus)

2019

196. KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer.

KATO K., SHAH M., ENZINGER P., BENNOUNA J., SHEN L., ADENIS A., et al.

Future oncology (London, England) , cilt.15, ss.1057-1066, 2019 (SCI-Expanded, Scopus)

2019

197. TITAN, a phase 3 study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT)

Merseburger A. S., Chowdhury S., Agarwal N., Bjartell A., Chung B. H., Pereira de Santana Gomes A. J., et al.

ONCOLOGY RESEARCH AND TREATMENT , cilt.42, ss.286, 2019 (SCI-Expanded, Scopus)

2018

198. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.

ANTONIA S., VILLEGAS A., DANIEL D., VICENTE D., MURAKAMI S., HUI R., et al.

The New England journal of medicine , cilt.379, ss.2342-2350, 2018 (SCI-Expanded, Scopus)

2018

199. Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study

Barlesi F., Vansteenkiste J., Spigel D., Ishii H., Garassino M., de Marinis F., et al.

LANCET ONCOLOGY , cilt.19, sa.11, ss.1468-1479, 2018 (SCI-Expanded, Scopus)

2018

200. Outcomes of Patients < 70 or >= 70 Years of Age in PACIFIC

Socinski M., Ozguroglu M., Villegas A., Daniel D., Vicente D., Murakami S., et al.

JOURNAL OF THORACIC ONCOLOGY , cilt.13, sa.10, 2018 (SCI-Expanded, Scopus)

2018

201. Everolimus Plus Exemestane vs Everolimus or Capecitabine Monotherapy for Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer: The BOLERO-6 Randomized Clinical Trial.

JERUSALEM G., de B., HURVITZ S., YARDLEY D., KOVALENKO E., EJLERTSEN B., et al.

JAMA oncology , cilt.4, ss.1367-1374, 2018 (SCI-Expanded, Scopus)

2018

202. Effect of Induction Chemotherapy in the PACIFIC Study

Spigel D., Vansteenkiste J., Reck M., Wakelee H., Ozguroglu M., Daniel D., et al.

JOURNAL OF THORACIC ONCOLOGY , cilt.13, sa.10, 2018 (SCI-Expanded, Scopus)

2018

203. Expanded Efficacy and Safety Analysis of PACIFIC Based on a PD-L1 Cutpoint of 25%

Spira A., Planchard D., Cho B. C., Ozguroglu M., Daniel D., Villegas A., et al.

JOURNAL OF THORACIC ONCOLOGY , cilt.13, sa.10, 2018 (SCI-Expanded, Scopus)

2018

204. Phase III KEYNOTE-590 study of chemotherapy + pembrolizumab versus chemotherapy + placebo as first-line therapy for patients (Pts) with advanced esophageal or esophagogastric junction (E/EGJ) cancer

Kato K., Shah M., Enzinger P., Bennouna J., Shen L., Adenis A., et al.

Annals of Oncology , cilt.29, 2018 (SCI-Expanded, Scopus)

2018

205. Overall Survival with Durvalumab Versus Placebo After Chemoradiotherapy in Stage III NSCLC: Updated Results from PACIFIC

Antonia S., Villegas A., Daniel D., Vicente D., Murakami S., Hui R., et al.

JOURNAL OF THORACIC ONCOLOGY , cilt.13, sa.10, 2018 (SCI-Expanded, Scopus)

2018

206. PACIFIC Subgroup Analysis: Pneumonitis in Stage III, Unresectable NSCLC Patients Treated with Durvalumab vs. Placebo After CRT

Vansteenkiste J., Naidoo J., Faivre-Finn C., Ozguroglu M., Villegas A., Daniel D., et al.

JOURNAL OF THORACIC ONCOLOGY , cilt.13, sa.10, 2018 (SCI-Expanded, Scopus)

2018

207. LATITUDE study: PSA response characteristics and correlation with overall survival (OS) and radiological progression-free survival (rPFS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) receiving ADT+abiraterone acetate and prednisone (AAP) or placebo (PBO)

Matsubara N., Chi K., Ozguroglu M., Rodriguez Antolin A., Feyerabend S., Fein L., et al.

Annals of Oncology , cilt.29, 2018 (SCI-Expanded, Scopus)

2018

208. Avelumab vs Docetaxel for Previously Treated Advanced NSCLC: Primary Analysis of the Phase 3 JAVELIN Lung 200 Trial

Barlesi F., Vansteenkiste J., Spigel D., Ishii H., Garassino M., De Marinis F., et al.

JOURNAL OF THORACIC ONCOLOGY , cilt.13, sa.10, 2018 (SCI-Expanded, Scopus)

2018

209. Metastatic Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy: Treatment Patterns From the PROXIMA Prospective Registry

Akaza H., Procopio G., Pripatnanont C., Facchini G., Fava S., Wheatley D., et al.

JOURNAL OF GLOBAL ONCOLOGY , cilt.4, 2018 (ESCI, Scopus)

2018

210. Results of the FLAC European Database of Metastatic Castration-Resistant Prostate Cancer Patients Treated With Docetaxel, Cabazitaxel, and Androgen Receptor-Targeted Agents

ANGELERGUES A., EFSTATHIOU E., GYFTAKI R., WYSOCKI P. J., LAINEZ N., GONZALEZ I., et al.

CLINICAL GENITOURINARY CANCER , cilt.16, sa.4, 2018 (SCI-Expanded, Scopus)

2018

211. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

SHITARA K., Ozguroglu M., BANG Y., DI BARTOLOMEO M., MANDALA M., RYU M., et al.

LANCET , cilt.392, sa.10142, ss.123-133, 2018 (SCI-Expanded, Scopus)

2018

212. Everolimus Plus Endocrine Therapy for Postmenopausal Women With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer A Clinical Trial

Royce M., BACHELOT T., VILLANUEVA C., Ozguroglu M., AZEVEDO S. J., CRUZ F. M., et al.

JAMA ONCOLOGY , cilt.4, sa.7, ss.977-984, 2018 (SCI-Expanded, Scopus)

2018

213. A phase 3 study of chemotherapy + pembrolizumab versus chemotherapy + placebo as first-line therapy for patients with advanced esophageal or esophagogastric junction (E/EGJ) cancer: KEYNOTE-590 - Trial in progress

Kato K., Shah M., Enzinger P., Bennouna J., Shen L., Adenis A., et al.

Annals of Oncology , cilt.29, 2018 (SCI-Expanded, Scopus)

2018

214. Pembrolizumab (pembro) vs paclitaxel (PTX) for previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer: Phase 3 KEYNOTE-061 trial.

Fuchs C. S., Ozguroglu M., Bang Y., Di Bartolomeo M., Mandala M., Ryu M., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.36, sa.15, 2018 (SCI-Expanded, Scopus)

2018

215. Afatinib in combination with pembrolizumab in patients (pts) with stage IIIB/IV squamous cell carcinoma (SCC) of the lung

Levy B. P., Paz-Ares L. G., Bennouna J., Felip E., Abreu D. R., Isla D., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.36, sa.15, 2018 (SCI-Expanded, Scopus)

2018

216. Everolimus (EVE) plus exemestane (EXE) vs EVE alone or capecitabine (CAP) for estrogen receptor-positive (ER plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): BOLERO-6, an open-label phase 2 study

Jerusalem G. H. M., Kovalenko E., Yardley D. A., De Boer R. H., Hurvitz S. A., Ejlertsen B., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.36, sa.15, 2018 (SCI-Expanded, Scopus)

2018

217. Longer term preplanned efficacy and safety analysis of abiraterone acetate plus prednisone (AA plus P) in patients (pts) with newly diagnosed high-risk metastatic castration-naive prostate cancer (NDx-HR mCNPC) from the phase 3 LATITUDE trial.

Fizazi K., Feyerabend S., Matsubara N., Ozguroglu M., Fein L. E., Antolin A. R., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.36, sa.15, 2018 (SCI-Expanded, Scopus)

2018

218. Subsequent treatment after abiraterone acetate plus prednisone (AA plus P) in patients (pts) with newly diagnosed high-risk metastatic castration-naive prostate cancer (NDx-HR mCNPC): Detailed analyses from the phase 3 LATITUDE trial.

Chi K. N., Namphuong Tran N. T., Feyerabend S., Matsubara N., Ozguroglu M., Fein L. E.

JOURNAL OF CLINICAL ONCOLOGY , cilt.36, sa.15, 2018 (SCI-Expanded, Scopus)

2018

219. Time to deterioration of symptoms with durvalumab in stage III, locally advanced, unresectable NSCLC: Post-hoc analysis of PACIFIC patient-reported outcomes

Hui R., Ozguroglu M., Villegas A., Daniel D., Vicente D., Murakami S., et al.

JOURNAL OF THORACIC ONCOLOGY , cilt.13, sa.4, 2018 (SCI-Expanded, Scopus)

2018

220. Durvalumab in Stage III Non-Small-Cell Lung Cancer.

Antonia S., Özgüroğlu M.

The New England journal of medicine , cilt.378, ss.869-870, 2018 (SCI-Expanded, Scopus)

2018

221. Durvalumab in Stage III Non-Small-Cell Lung Cancer REPLY

Antonia S. J., Ozguroglu M.

NEW ENGLAND JOURNAL OF MEDICINE , cilt.378, sa.9, ss.869-870, 2018 (SCI-Expanded, Scopus)

2017

222. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Martin M., Holmes F. A., Ejlertsen B., Delaloge S., Moy B., Iwata H., et al.

The Lancet Oncology , cilt.18, sa.12, ss.1688-1700, 2017 (SCI-Expanded, Scopus)

2017

223. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer

Antonia S. J., Villegas A., Daniel D., Vicente D., Murakami S., Hui R., et al.

NEW ENGLAND JOURNAL OF MEDICINE , cilt.377, sa.20, ss.1919-1929, 2017 (SCI-Expanded, Scopus)

2017

224. Patient-Reported Outcomes with Durvalumab after Chemoradiation in Locally Advanced, Unresectable NSCLC: Data from PACIFIC

Hui R., Ozguroglu M., Daniel D., Baz D., Murakami S., Yokoi T., et al.

JOURNAL OF THORACIC ONCOLOGY , cilt.12, sa.11, 2017 (SCI-Expanded, Scopus)

2017

225. Everolimus (EVE) + letrozole (LET) in patients (pts) with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer (ABC): Progression-free survival (PFS) subgroup analyses in BOLERO-4

Bachelot T., Royce M., Villanueva C., Melo Cruz F., Hegg R., Falkson C., et al.

Annals of Oncology , cilt.28, 2017 (SCI-Expanded, Scopus)

2017

226. LATITUDE, a phase 3 double-blind, randomized trial of androgen deprivation therapy (ADT) with abiraterone acetate (AA) plus prednisone (P) or placebos (PBOs) in patients (pts) with newly diagnosed high-risk metastatic hormone-naive prostate cancer (mHNPC)

Feyerabend S., Tran N., Fein L., Matsubara N., Rodriguez Antolin A., Alekseev B., et al.

ONCOLOGY RESEARCH AND TREATMENT , cilt.40, ss.113, 2017 (SCI-Expanded, Scopus)

2017

227. Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer

Fizazi K., NamPhuong Tran N. T., Fein L., Matsubara N., Rodriguez-Antolin A., Alekseev B. Y., et al.

NEW ENGLAND JOURNAL OF MEDICINE , cilt.377, sa.4, ss.352-360, 2017 (SCI-Expanded, Scopus)

2017

228. Prognostic Value of Baseline Neutrophil-to-Lymphocyte Ratio in Metastatic Urothelial Carcinoma Patients Treated With First-line Chemotherapy: A Large Multicenter Study

Auvray M., Elaidi R., Ozguroglu M., Guven S., Gauthier H., Culine S., et al.

CLINICAL GENITOURINARY CANCER , cilt.15, sa.3, 2017 (SCI-Expanded, Scopus)

2017

229. LATITUDE: A phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer.

Fizazi K., Namphuong Tran N. T., Enrique Fein L., Matsubara N., Rodriguez Antolin A., Alekseev B. Y., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.35, sa.18, 2017 (SCI-Expanded, Scopus)

2017

230. Sequencing in metastatic castration-resistant prostate cancer (mCRPC): Updated results of the FLAC International Database.

Delanoy N., Angelergues A., Efstathiou E., Gyftaki R., Wysocki P. J., Lainez N., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.35, sa.6_suppl, ss.1, 2017 (SCI-Expanded, Scopus)

2016

231. BOLERO-4: Phase 2 trial of first-line everolimus (EVE) plus letrozole (LET) in estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2-) advanced breast cancer (BC)

Royce M., Villanueva C., Ozguroglu M., Bachelot T., Azevedo S., Melo Cruz F., et al.

Annals of Oncology , cilt.27, 2016 (SCI-Expanded, Scopus)

2016

232. COST OF TREATMENT OF HR+/HER2-POST MENOPAUSAL ADVANCED/METASTATIC BREAST CANCER PATIENTS IN TURKEY

Altundag K., Basaran G., Oksuzoglu B., Oven B., Ozguroglu M., Aydin D., et al.

VALUE IN HEALTH , cilt.19, sa.3, 2016 (SCI-Expanded, SSCI, Scopus)

2015

233. Clinical experience with Vemurafenib in pretreated melanoma (MEL): The results of open label multi center study from Turkey.

Celik I., Mandel N. M., Gokmen E., Unal O. U., Sevinc A., Coskun H. S., et al.

Journal of Clinical Oncology , cilt.33, sa.15_suppl, 2015 (SCI-Expanded, Scopus)

2015

234. Is perineural invasion (PN) a determinant of disease free survival in early stage colorectal cancer?

Ozturk M. A., DANE F., Karagoz S., Tural D., Selcukbiricik F., Demirelli F., et al.

Hepato-Gastroenterology , cilt.62, sa.137, ss.59-64, 2015 (SCI-Expanded, Scopus)

2014

235. Retraction Note: Clinical significance of p95HER2 overexpression, PTEN loss and PI3K expression in p185HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies

Tural D., Serdengecti S., Demirelli F., Öztürk T., İlvan S., Turna H., et al.

British Journal of Cancer , cilt.110, sa.12, 2014 (SCI-Expanded, Scopus)

2014

236. Prostate-specific antigen flare induced by cabazitaxel-based chemotherapy in patients with metastatic castration-resistant prostate cancer

Angelergues A., Maillet D., Flechon A., Ozguroglu M., Mercier F., Guillot A., et al.

EUROPEAN JOURNAL OF CANCER , cilt.50, sa.9, ss.1602-1609, 2014 (SCI-Expanded, Scopus)

2014

237. Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial

Andre F., O'Regan R., Ozguroglu M., Toi M., Xu B., Jerusalem G., et al.

LANCET ONCOLOGY , cilt.15, sa.6, ss.580-591, 2014 (SCI-Expanded, Scopus)

2014

238. Quality-of-life in Turkish cancer patients: The impact of sociodemographic characteristics, medical history, and management Türk kanser hastalari{dotless}nda sosyodemografik karakteristiklerin, ti{dotless}bbi öykünün ve tedavilerin yaşam kalitesi üzerine etkisi

Toptas T., Yildiz I., Yildiz M., Varol U., Bayoglu I. V., Ozguroglip M.

UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi , cilt.24, sa.1, ss.23-29, 2014 (SCI-Expanded, Scopus, TRDizin)

2014

239. Receptor expression discrepancy between primary and metastatic breast cancer lesions

Ozen D. S. K., Öztürk M. S., Aydin O., Turna Z. H., Ilvan Ş., Ozguroglu M.

Oncology Research and Treatment , cilt.37, sa.11, ss.622-626, 2014 (SCI-Expanded, Scopus)

2014

240. Clinical significance of p95HER2 overexpression, PTEN loss and PI3K expression in p185HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies.

Tural D., Serdengecti S., Demirelli F. H., Öztürk T., Ilvan Ş., Turna H., et al.

British journal of cancer , cilt.110, sa.8, ss.1968-1976, 2014 (SCI-Expanded, Scopus)

2013

241. BOLERO-3: Quality-of-life maintained in patients with metastatic breast cancer treated with everolimus plus trastuzumab plus vinorelbine

Isaacs C., Ozguroglu M., Jerusalem G., Xu B., Lang I., O'Regan R., et al.

CANCER RESEARCH , cilt.73, 2013 (SCI-Expanded, Scopus)

2013

242. Dendritic cell sarcoma: A pooled analysis including 462 cases with presentation of our case series

Saygin C., Uzunaslan D., Ozguroglu M., Senocak M., Tuzuner N.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY , cilt.88, sa.2, ss.253-271, 2013 (SCI-Expanded, Scopus)

2013

243. Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial

Bahl A., Oudard S., Tombal B., Ozguroglu M., Hansen S., Kocak I., et al.

ANNALS OF ONCOLOGY , cilt.24, sa.9, ss.2402-2408, 2013 (SCI-Expanded, Scopus)

2013

244. Evaluation of everolimus (EVE) in HER2+advanced breast cancer (BC) with activated PI3K/mTOR pathway: Exploratory biomarker observations from the BOLERO-3 trial

Jerusalem G., Andre F., Chen D., Robinson D., Ozguroglu M., Lang I., et al.

EUROPEAN JOURNAL OF CANCER , cilt.49, 2013 (SCI-Expanded, Scopus)

2013

245. Prognostic factors of survival in patients with metastatic castration resistant prostate cancer (mCRPC) treated with cabazitaxel: Sequencing might matter.

Angelergues A., Maillet D., Flechon A., Ozguroglu M., Mercier F., Guillot A., et al.

Journal of Clinical Oncology , cilt.31, sa.15_suppl, 2013 (SCI-Expanded, Scopus)

2013

246. Phase III, randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and vinorelbine in trastuzumab-resistant, advanced breast cancer (BOLERO-3).

O'Regan R., Ozguroglu M., Andre F., Toi M., Jerusalem G. H. M., Wilks S., et al.

Journal of Clinical Oncology , cilt.31, sa.15_suppl, 2013 (SCI-Expanded, Scopus)

2013

247. Clinicopathological features and outcomes of patients with gastric cancer: A single-center experience

Selcukbiricik F., Buyukunal E., Tural D., Ozguroglu M., Demirelli F., Serdengecti S.

WORLD JOURNAL OF GASTROENTEROLOGY , cilt.19, sa.14, ss.2154-2161, 2013 (SCI-Expanded, Scopus)

2013

248. Patterns of complementary and alternative medicine use among turkish cancer patients

Yildiz I., Ozguroglu M., TOPTAŞ T., Turna H., Sen F., Yildiz M.

Journal of Palliative Medicine , cilt.16, sa.4, ss.383-390, 2013 (SCI-Expanded, Scopus)

2013

249. Preoperative chemoradiotherapy improves local recurrence free survival in locally advanced rectal cancer

Tural D., Ozturk M., Selcukbiricik F., Yildiz O., Elicin O., Turna H., et al.

JOURNAL OF BUON , cilt.18, sa.2, ss.385-390, 2013 (SCI-Expanded, Scopus)

2013

250. Primary osteosarcoma of the heart: Experience of an unusual case

Özen D. S. K., Öztürk M. A., Selcukbiricik F., Esatoglu S. N., Turna Z. H., Beyaz P., et al.

Case Reports in Oncology , cilt.6, sa.1, ss.224-228, 2013 (SCI-Expanded, ESCI, Scopus)

2013

251. Clinicopathological Features and Localization of Gastric Cancers and their Effects on Survival in Turkey

SELÇUKBİRİCİK F., Tural D., Bilici A., Uzel E. K., Ozguroglu M., Demirelli F., et al.

ASIAN PACIFIC JOURNAL OF CANCER PREVENTION , cilt.14, sa.1, ss.553-556, 2013 (SCI-Expanded, Scopus)

2013

252. The role of K-RAS and B-RAF mutations as biomarkers in metastatic colorectal cancer

Selcukbiricik F., Erdamar S., Ozkurt C. U., Mandel N. M., Demirelli F. H., Ozguroglu M., et al.

JOURNAL OF BUON , cilt.18, sa.1, ss.116-123, 2013 (SCI-Expanded, Scopus)

2012

253. Aflibercept and Docetaxel Versus Docetaxel Alone After Platinum Failure in Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer: A Randomized, Controlled Phase III Trial

Ramlau R., Gorbunova V., Ciuleanu T. E., Novello S., Ozguroglu M., GÖKSEL T., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.30, sa.29, ss.3640-3647, 2012 (SCI-Expanded, Scopus)

2012

254. Impact of Cabazitaxel (CBZ) + Prednisone (P; CBZP) on Overall Survival (OS) At 2 Yrs and in Patients (PTS) with Aggressive Disease: Post-Hoc Analyses of Tropic Trial

Oudard S., de Bono J., Özgüroglu M., Hansen S., Machiels J., Kocak I., et al.

Annals of Oncology , cilt.23, 2012 (SCI-Expanded, Scopus)

2012

255. Thromboembolic complications in cancer patients.

Yenidunya G., Turna H., Ozturk M. A., Tural D., Selcukbiricik F., Yildiz O., et al.

Journal of Clinical Oncology , cilt.30, sa.15_suppl, 2012 (SCI-Expanded, Scopus)

2012

256. A cohort compassionate-use program with cabazitaxel plus prednisone for patients with metastatic castration-resistant prostate cancer: Interim results.

Bavbek S. E., Malik Z. I., Di Lorenzo G., Scholz H., van Oort I. M., Ng S., et al.

Journal of Clinical Oncology , cilt.30, sa.15_suppl, 2012 (SCI-Expanded, Scopus)

2012

257. Phase II Study of Loading-Dose Ibandronate Treatment in Patients with Breast Cancer and Bone Metastases Suffering from Moderate to Severe Pain

Altundag K., DİZDAR Ö., ÖZSARAN Z., ÖZKÖK S., Saip P., Eralp Y., et al.

ONKOLOGIE , cilt.35, sa.5, ss.254-258, 2012 (SCI-Expanded, Scopus)

2012

258. A cohort compassionate-use program with cabazitaxel plus prednisone for patients with metastatic castration-resistant prostate cancer: Interim results.

Bavbek S. E., Malik Z., Di Lorenzo G., Scholz H., van Oort I. M., Ng S., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.30, sa.5, 2012 (SCI-Expanded, Scopus)

2012

259. Prognostic factors for survival in the phase III TROPIC trial.

Sartor A. O., Oudard S., Ozguroglu M., Hansen S., Machiels J. H., Kocak I., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.30, sa.5, 2012 (SCI-Expanded, Scopus)

2012

260. UNUSUAL PRESENTATION OF CERVICAL CARCINOMA METASTASIS TO THE BREAST: A CASE REPORT AND REVIEW OF THE LITERATURE

Yetmen O., Oksuz D., Demirkiran F., Ozguroglu M., Calay Z., Atkovar G., et al.

JOURNAL OF BREAST HEALTH , cilt.8, sa.2, ss.92-96, 2012 (ESCI, TRDizin)

2012

261. Primary gastric lymphoma: conservative treatment modality is not inferior to surgery for early-stage disease.

SELCUKBIRICIK F., TURAL D., ELICIN O., BERK S., Ozgüroğlu M., BESE N., et al.

ISRN oncology , cilt.2012, ss.951816, 2012 (Hakemli Dergi)

2012

262. Serviks kanserinin memeye sıra dışı metastazı: Olgu sunumu ve literatür değerlendirilmesi.

Yetmen Ö., ÇOLPAN ÖKSÜZ D., DEMİRKIRAN F., ÖZGÜROĞLU M., CALAY Z. Z., ATKOVAR G., et al.

Meme Sağlığı Dergisi , sa.8, ss.92-96, 2012 (SCI-Expanded, TRDizin)

2011

263. Synchronous detection of hairy cell leukemia and HIV-negative Kaposi's sarcoma of the lymph node: A diagnostic challenge and a rare coincidence

Aydin S. O., Eskazan A. E., Aki H., Ozguroglu M., Baslar Z., Soysal T.

Case Reports in Oncology , cilt.4, sa.3, ss.439-444, 2011 (SCI-Expanded, Scopus)

2011

264. AFLIBERCEPT IN COMBINATION WITH DOCETAXEL FOR SECOND-LINE TREATMENT OF LOCALLY ADVANCED OR METASTATIC NON-SMALL-CELL LUNG CANCER (NSCLC): FINAL RESULTS OF A MULTINATIONAL PLACEBO-CONTROLLED PHASE III TRIAL (EFC10261-VITAL)

Novello S., Ramlau R., Gorbunova V. A., Ciuleanu T. E., Ozguroglu M., GÖKSEL T., et al.

JOURNAL OF THORACIC ONCOLOGY , cilt.6, sa.6, 2011 (SCI-Expanded, Scopus)

2011

265. A subgroup analysis of the TROPIC trial exploring reason for discontinuation of prior docetaxel and survival outcome of cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC).

De Bono J. S., Oudard S., Ozguroglu M., Hansen S., Machiels J. H., Shen L., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.29, sa.15, 2011 (SCI-Expanded, Scopus)

2011

266. Survival benefit from first docetaxel treatment for cabazitaxel plus prednisone compared with mitoxantrone plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) enrolled in the TROPIC trial.

Sartor A. O., Oudard S., Ozguroglu M., Hansen S., Machiels J. H., Shen L., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.29, sa.15, 2011 (SCI-Expanded, Scopus)

2011

267. Impact of G-CSF prophylaxis on the occurrence of neutropenia in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel.

Ozguroglu M., Oudard S., Sartor A. O., Hansen S., Machiels J. H., Shen L., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.29, sa.15, 2011 (SCI-Expanded, Scopus)

2011

268. CLINICAL BENEFIT OF CABAZITAXEL PLUS PREDNISONE IN THE TROPIC TRIAL IN MEN WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC) WHO PROGRESSED AFTER DOCETAXEL-BASED TREATMENT

Tombal B., Oudard S., Ozguroglu M., Hansen S., Kocak I., Gravis G., et al.

EUROPEAN UROLOGY SUPPLEMENTS , cilt.10, sa.2, ss.335-336, 2011 (SCI-Expanded)

2011

269. Effect of G-CSF prophylaxis on the occurrence of neutropenia in men receiving cabazitaxel plus prednisone for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in the TROPIC study

Ozguroglu M., Oudard S., Sartor A. O., Hansen S., Machiels J. H., Shen L., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.29, sa.7, 2011 (SCI-Expanded, Scopus)

2011

270. 1090 CLINICAL BENEFIT OF CABAZITAXEL PLUS PREDNISONE IN THE TROPIC TRIAL IN MEN WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC) WHO PROGRESSED AFTER DOCETAXEL-BASED TREATMENT

Tombal B., Oudard S., Ozguroglu M., Hansen S., Kocak I., Gravis G., et al.

European Urology Supplements , cilt.10, sa.2, 2011 (SCI-Expanded)

2010

271. Gastroenteropancreatic Neuroendocrine tumors: 10-Year experience in a single center

Yildiz O., Ozguroglu M., Yanmaz T., Turna H., Serdengecti S., Dogusoy G.

Medical Oncology , cilt.27, sa.4, ss.1050-1056, 2010 (SCI-Expanded, Scopus)

2010

272. Primary diffuse large B cell lymphoma of the breast eight years after the diagnosis of gastric MALT lymphoma: Report of first case

Bilici A., Ozguroglu M., Tuzuner N., Goksel S., Turna H.

Archives of Gynecology and Obstetrics , cilt.282, sa.5, ss.587-590, 2010 (SCI-Expanded, Scopus)

2010

273. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

de Bono J. S., Oudard S., Ozguroglu M., Hansen S., Machiels J., Kocak I., et al.

LANCET , cilt.376, sa.9747, ss.1147-1154, 2010 (SCI-Expanded, Scopus)

2010

274. Cabazitaxel or mitoxantrone with prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: Final results of a multinational phase III trial (TROPIC)

De Bono J. S., Oudard S., Ozguroglu M., Hansen S., Machiels J. H., Shen L., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.28, sa.15, 2010 (SCI-Expanded, Scopus)

2010

275. Phase II study of loading-dose ibandronate treatment in patients in breast cancer and bone metastases suffering from moderate to severe pain

Dizdar O., Altundag M. K., Ozkok S., Ozsaran Z., Saip P., Eralp Y., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.28, sa.15, 2010 (SCI-Expanded, Scopus)

2010

276. How does (18)f-FDG PET-CT scan affect clinical judgment and change treatment decisions in patients with epithelial ovarian cancer?

Selcukbiricik F., Ozguroglu M., Ozturk M. A., Ozgur N., Turna H., Tural D., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.28, sa.15, 2010 (SCI-Expanded, Scopus)

2010

277. Surgery for isolated liver metastasis of ovarian cancer

Pekmezci S., Saribeyoglu K., Aytac E., Arvas M., Demirkiran F., Ozguroglu M.

Asian Journal of Surgery , cilt.33, sa.2, ss.83-88, 2010 (SCI-Expanded, Scopus)

2010

278. The treatment results of postoperative chemoradiotherapy in gastric carcinoma: Cerrahpaşa experience Mide karsinomlarinda postoperatif kemoradyoterapi tedavi sonuçlari: Cerrahpaşa deneyimi

Çolpan Öksüz D., Eren M. F., Şenel Beşe N., Büyükünal E., Özgüroǧlu M., Molinas Mandel N., et al.

Turk Onkoloji Dergisi , cilt.25, sa.1, ss.1-10, 2010 (SCI-Expanded, Scopus)

2010

279. The treatment results of postoperative chemoradiotherapy in gastric carcinoma: Cerrahpasa experience

Oksuz D., Eren M. F., Bese N. S., Buyukunal E., Ozguroglu M., Mandel N. M., et al.

TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY , cilt.25, sa.1, ss.1-10, 2010 (ESCI, Scopus)

2010

280. Mide karsinomlarında postoperatif kemoradyoterapi tedavi sonuçları: Cerrahpaşa deneyimi

ÇOLPAN ÖKSÜZ D., Eren M. F., BEŞE F. N., BÜYÜKÜNAL E., ÖZGÜROĞLU M., Mandel N. M., et al.

TÜRK ONKOLOJİ DERGİSİ , sa.25, ss.1-10, 2010 (Scopus)

2009

281. Is There Any Effect of Tumor Burden on Hemostatic Parameters in Cancer Patients? A Case Control Study of Hemostatic Abnormalities and Anticardiolipin Antibodies in Solid Tumors. "

TURNA Z. H., ÖZGÜROĞLU M., BOLAYIRLI İ. M., ORHANOĞLU T., BALCI H.

CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS , cilt.15, ss.454-457, 2009 (SCI-Expanded, Scopus)

2009

282. Is there any effect of tumor burden on hemostatic parameters in cancer patients? a caseĝ€"control study of hemostatic abnormalities and anticardiolipin antibodies in solid tumors

Turna H., Ozguroglu M., Bolayirli M., Orhanoglu T., Balci H.

Clinical and Applied Thrombosis/Hemostasis , cilt.15, sa.4, ss.454-457, 2009 (SCI-Expanded, Scopus)

2009

283. Is There Any Effect of Tumor Burden on Hemostatic Parameters in Cancer Patients? A Case–Control Study of Hemostatic Abnormalities and Anticardiolipin Antibodies in Solid Tumors

TURNA Z. H., ÖZGÜROĞLU M., BOLAYIRLI İ. M., ORHANOĞLU T., BALCI H.

CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS , cilt.15, sa.4, ss.454-457, 2009 (SCI-Expanded, Scopus)

2008

284. Metastasis from breast carcinoma to endometrial polyp

Aydin O., Bagci P., Akyildiz E. U., Ozguroglu M., Ilvan Ş.

European Journal of Gynaecological Oncology , cilt.29, sa.6, ss.666-668, 2008 (SCI-Expanded, Scopus)

2008

285. Diagnostic value of magnetic resonance imaging and scintigraphy in patients with metastatic breast cancer of the axial skeleton: A comparative study

Yilmaz M. H., Ozguroglu M., Mert D., Turna H., Demir G., Adaletli I., et al.

Medical Oncology , cilt.25, sa.3, ss.257-263, 2008 (SCI-Expanded, Scopus)

2008

286. Determining predominating histologic component in malignant mixed müllerian tumors: Is it worth it?

Ozguroglu M., Bilici A., Ilvan Ş., Turna H., Atalay B., Mandel N., et al.

International Journal of Gynecological Cancer , cilt.18, sa.4, ss.809-812, 2008 (SCI-Expanded, Scopus)

2007

287. A case-control study of non-alcoholic fatty liver disease in breast cancer

Bilici A., Ozguroglu M., Mihmanh I., Turna H., Adaletli I.

Medical Oncology , cilt.24, sa.4, ss.367-371, 2007 (SCI-Expanded, Scopus)

2007

288. Neuroblastoma in adults, presentation of 2 cases

Demir H., Aydin O., Durak H., Dervisoglu S., Ozguroglu M., Sahinler İ.

VIRCHOWS ARCHIV , sa.2, ss.577, 2007 (SCI-Expanded, Scopus)

2007

289. Paraneoplastic pemphigus associated with fludarabine use

Yıldız O., Özgüroğlu M., Yanmaz M. R., Turna H., Kursunoglu S. G., Antonov M., et al.

Medical Oncology , cilt.24, sa.1, ss.115-118, 2007 (SCI-Expanded, Scopus)

2007

290. Thymoma with chronic diarrhea: Report of two cases and review of the literature

Yildiz O., Ozguroglu M., TURNA H., YANMAZ T., Kaynak K., Akman C., et al.

Medical Oncology , cilt.24, sa.1, ss.119-123, 2007 (SCI-Expanded, Scopus)

2007

291. The role of US and MR imaging in detecting local chest wall tumor recurrence after mastectomy

Yilmaz M. H., Esen G., Ayarcan Y., Aydogan F., Ozguroglu M., Demir G., et al.

DIAGNOSTIC AND INTERVENTIONAL RADIOLOGY , cilt.13, sa.1, ss.13-18, 2007 (SCI-Expanded, Scopus)

2007

292. P-20 Unusual pattern of skin metastasis as reticular hyperpigmentation in a case of melanoma

Ozguroglu M., Ozguroglu E., Ince U.

Melanoma Research , cilt.17, sa.1, 2007 (SCI-Expanded, Scopus)

2007

293. C-reactive protein as an acute phase protein in cancer patients

Bolayirli M., Turna H., ORHANOĞLU T., Ozaras R., İLHAN M., Ozguroglu M.

Medical Oncology , cilt.24, sa.3, ss.338-344, 2007 (SCI-Expanded, Scopus)

2006

294. Megestrol acetate induced hypoadrenalism with cushingoid phenotype in endometrial cancer [1]

Ozguroglu M., Yildiz O., Turna H., Kadioglu P.

Gynecologic Oncology , cilt.101, sa.1, ss.183, 2006 (SCI-Expanded, Scopus)

2006

295. US and MRI Findings in chest wall recurrences in breast cancer patients treated with mastectomy

Esen G., Yilmaz , Gurses B., Ozguroglu M., Demir G., Mandel N., et al.

European Journal of Cancer Supplements , cilt.4, sa.2, 2006 (SCI-Expanded, Scopus)

2006

296. Devastating effects of chemotherapy: Deafness and acute renal failure in a patient with epithelial ovarian cancer

Ozguroglu M., Sari O., Turna H.

International Journal of Gynecological Cancer , cilt.16, ss.394-396, 2006 (SCI-Expanded, Scopus)

2006

297. Small cell carcinoma of the bladder: A case report and review of the literature

Tunc B., Ozguroglu M., Demirkesen O., Alan C., Durak H., Dincbas F. O., et al.

International Urology and Nephrology , cilt.38, sa.1, ss.15-19, 2006 (SCI-Expanded, Scopus)

2006

298. Adult paratesticular myxofibrosarcoma: report of a rare entity and review of the literature.

OZKAN B., OZGÜROĞLU M., Ozkara H., DURAK H., TALAT Z.

International urology and nephrology , cilt.38, ss.5-7, 2006 (SCI-Expanded, Scopus)

2006

299. Skeletal muscle: An unusual site of distant metastasis in gastric carcinoma

Beşe N. Ş., Özgüroĝlu M., Dervişoĝlu S., Kanberoǧlu K., Öber A.

Radiation Medicine - Medical Imaging and Radiation Oncology , cilt.24, sa.2, ss.150-153, 2006 (Scopus)

2005

300. Toxicity and survival results of a phase II study investigating the role of postoperative chemoradioimmunotherapy for gastric adenocarcinoma

Bese N., Buyukunal E., Ozguroglu M., Demir G., Yildirim A., Mandel N. K., et al.

STRAHLENTHERAPIE UND ONKOLOGIE , cilt.181, sa.10, ss.652-659, 2005 (SCI-Expanded, Scopus)

2005

301. Idiopathic thrombocytopenia associated with dysgerminoma in a patient with androgen insensitivity syndrome

Yildiz O., Ozguroglu M.

GYNECOLOGIC ONCOLOGY , cilt.99, sa.1, ss.248, 2005 (SCI-Expanded, Scopus)

2005

302. Acute phase proteins in malignancy: role of CRP in the discrimination of infectious complications in cancer patients

Ozguroglu M., Bolayirli M., Orhanoglu T., Yildiz O., Turna H., Serdengecti S.

EJC SUPPLEMENTS , cilt.3, sa.2, ss.70, 2005 (SCI-Expanded, Scopus)

2005

303. Secretory carcinoma of the breast. Case report and review of the literature

Ozguroglu M., Tascilar K., Ilvan S., Soybir G., Celik V.

Oncology , cilt.68, ss.263-268, 2005 (SCI-Expanded, Scopus)

2005

304. Delayed onset bleomycin-induced pneumonitis

Uzel I., Ozguroglu M., Uzel B., Kaynak K., Demirhan O., Akman C., et al.

UROLOGY , cilt.66, sa.1, 2005 (SCI-Expanded, Scopus)

2005

305. Role of the antiangiogenetic drug paclitaxel on healing of intestinal anastomosis: An experimental study

Yüceyar S., ERTÜRK Ş. M., Temiz M., Doğusoy G., Gümüştaş K., Özgüroǧlu M., et al.

Techniques in Coloproctology , cilt.9, sa.3, ss.201-205, 2005 (SCI-Expanded, Scopus)

2005

306. Does the incidence of anal canal cancers differ in Moslem societies?

Yumuk P., Abacioglu U., Demir G., Cabuk D., Dane F., Gumus M., et al.

INTERNATIONAL JOURNAL OF COLORECTAL DISEASE , cilt.20, sa.1, ss.76, 2005 (SCI-Expanded, Scopus)

2004

307. Rituximab-induced tumor progression: Does it really happen?

Ozguroglu M., Turna H.

Medical Oncology , cilt.21, sa.2, ss.205-206, 2004 (SCI-Expanded, Scopus)

2004

308. Gastric cancer in Turkey: A single center experience of 683 cases

Demir G., Buyukunal E., Kizilkilic E., Ozguroglu M., Mandel N., Demirelli F., et al.

Journal of Clinical Oncology , cilt.22, sa.14_suppl, 2004 (SCI-Expanded, Scopus)

2004

309. Is the incidence of anal canal cancers different in Moslem societies?

Cabuk D., Yumuk P. F., Abacioglu U., Demir G., Dane F., Gumus M., et al.

Journal of Clinical Oncology , cilt.22, sa.14_suppl, 2004 (SCI-Expanded, Scopus)

2004

310. Reactivation of hepatitis B virus infection with cytotoxic therapy in non-Hodgkin's lymphoma

Ozguroglu M., Bilici A., Turna H., Serdengecti S.

Medical Oncology , cilt.21, sa.1, ss.67-72, 2004 (SCI-Expanded, Scopus)

2004

311. Do we really benefit from checking tumor markers in detecting recurrence in gastrointestinal cancer?

Ozguroglu M., Turna H.

Journal of B.U.ON. , cilt.9, sa.2, ss.179-182, 2004 (SCI-Expanded, Scopus)

2004

312. Mismanagement of cancer pain: Attitudes of physicians and perception of pain and its treatment by the cancer patients

Serdengecti S., Ozguroglu M., Toptas T., Velet M., Yanmaz T., Buyukunal E.

ANNALS OF ONCOLOGY , cilt.15, ss.211-212, 2004 (SCI-Expanded, Scopus)

2004

313. Acute leukemia in a patient with ocular melanoma - Is it induced by Intraocular Brachytherapy or only a bad fate?

Ozguroglu M., Bese N., Karacam S., Pazarli H.

MEDICAL ONCOLOGY , cilt.21, sa.4, ss.373-374, 2004 (SCI-Expanded, Scopus)

2004

314. Multiple primary tumors in cancer patients in a Turkish population

Ozguroglu M., Donmez H., Turna H., Mandel N.

ANNALS OF ONCOLOGY , cilt.15, ss.149, 2004 (SCI-Expanded, Scopus)

2004

315. Should mammographic screening be done in primary ovarian cancer? A case control study in Turkish women

Ozguroglu M., Avci B., Turna H., Esen G., Arun B., Celik V., et al.

Medical Oncology , cilt.21, sa.2, ss.139-143, 2004 (SCI-Expanded, Scopus)

2003

316. Pentoxifylline in the Treatment of Radiation-related Pelvic Insufficiency Fractures of Bone

Beşe N. Ş., Özgüroǧlu M., Kamberoǧlu K., Karahasanoglu T., Öber A.

Radiation Medicine - Medical Imaging and Radiation Oncology , cilt.21, sa.5, ss.223-227, 2003 (Scopus)

2003

317. 188 Determining predominating histologic component in malignant mixed mullerian tumors: does it really work?

Ozguroglu M., Bilici A., Sennur I., Turna H., Mandel N., Serdengecti S.

European Journal of Cancer Supplements , cilt.1, sa.5, 2003 (Scopus)

2003

318. Intrathoracic extravasation of antineoplastic agents - Case report and systematic review

Bozkurt A., Uzel B., Akman C., Ozguroglu M., Mandel N.

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS , cilt.26, sa.2, ss.121-123, 2003 (SCI-Expanded, Scopus)

2002

319. Primary granulocytic sarcoma of the urinary bladder: case report and review of the literature.

Aki H., BASLAR Z., UYGUN N., OZGUROGLU M., TUZUNER N.

Urology , cilt.60, ss.345, 2002 (SCI-Expanded, Scopus)

2002

320. Flutamide-induced acute renal failure in a patient with metastatic prostate cancer.

Altiparmak M. R., Bilici A., Kisacik B., Ozguroglu M.

Medical oncology (Northwood, London, England) , cilt.19, sa.2, ss.117-9, 2002 (SCI-Expanded, Scopus)

2002

321. Simultaneous presentation of hepatocellular carcinoma in identical twin brothers

Demir G., Belentepe S., Ozguroglu M., Celik A. F., Sayhan N., Tekin S., et al.

MEDICAL ONCOLOGY , cilt.19, sa.2, ss.113-116, 2002 (SCI-Expanded, Scopus)

2001

322. Metastatic cardiac myxoma

KAYNAK K., BESIRLI K., ARSLAN C., OZGUROGLU M., Oz B.

ANNALS OF THORACIC SURGERY , cilt.72, sa.2, ss.623-625, 2001 (SCI-Expanded, Scopus)

2001

323. Continous accelerated hyperfractionated radiotherapy (CHART) plus chemotherapy (CT) with vinorelbine (VB) and cisplatinum (CDDP) in locally advanced NSCLC (TOG-011 study)

Oner Dincbas F., Koca S., Altinel A., Hancilar T., Cavusoglu M., Turhal S., et al.

European Journal of Cancer , cilt.37, 2001 (SCI-Expanded, Scopus)

2000

324. Serum erythropoietin level in anemic cancer patients

Ozguroglu M., Arun B., Demir G., Demirelli F. H., Mandell N., Buyukunal E., et al.

MEDICAL ONCOLOGY , cilt.17, sa.1, ss.29-34, 2000 (SCI-Expanded, Scopus)

1999

325. Usefulness of the epithelial tumor marker CA-125 in non-Hodgkin's lymphoma

Ozguroglu M., Turna H., Demir G., Doventas A., Demirelli F. H., Mandel N. K., et al.

American Journal of Clinical Oncology: Cancer Clinical Trials , cilt.22, sa.6, ss.615-618, 1999 (SCI-Expanded, Scopus)

1999

326. Vinorelbine plus infusional 5-fluorouracil in anthracycline and taxane refractory metastatic breast cancer: A pilot study

Ozguroglu M., Demir G., Demirelli F., Molinas Mandel N., Buyukunal E., Serdengecti S., et al.

Journal of B.U.ON. , cilt.4, sa.4, ss.367-372, 1999 (SCI-Expanded, Scopus)

1999

327. Paraneoplastic hyperpigmentation secondary to lung cancer resolving after chemotherapy

Ozguroglu M., Tahan V., Ozguroglu E., Ozaras R., Demir G.

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS , cilt.22, sa.5, ss.533-534, 1999 (SCI-Expanded, Scopus)

1999

328. Serum erythropoietin level in anemic cancer patients

Ozguroglu M., Demir G., Demirelli F., Molinas-Mandel N., Buyukunal E., Serdengecti S., et al.

EUROPEAN JOURNAL OF CANCER , cilt.35, 1999 (SCI-Expanded, Scopus)

1999

329. Anorectal melanoma metastatic to the breast

Ozguroglu M., Ozaras R., Tahan V., Demirkesen C., Demir G., Dogusoy G., et al.

JOURNAL OF CLINICAL GASTROENTEROLOGY , cilt.29, sa.2, ss.197-199, 1999 (SCI-Expanded, Scopus)

1999

330. Chemoimmunotherapy protocol for advanced gastric cancer

Demir G., Ozguroglu M., Molinas-Mandel N., Relli F., Buyukunal E., Serdengecti S., et al.

EUROPEAN JOURNAL OF CANCER , cilt.35, 1999 (SCI-Expanded, Scopus)

1999

331. Role of mammographic screening in ovarian cancer

Ozguroglu M., Esen G., Yildirim B., Demir G., Turna H., Demirelli F., et al.

EUROPEAN JOURNAL OF CANCER , cilt.35, 1999 (SCI-Expanded, Scopus)

1999

332. Bilateral inflammatory breast metastases of epithelial ovarian cancer

Ozguroglu M., Ersavasti G., Ilvan S., Hatemi G., Demir G., Demirelli F. H.

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS , cilt.22, sa.4, ss.408-410, 1999 (SCI-Expanded, Scopus)

1999

333. Expression of p53 protein and resistance to preoperative chemotherapy in locally advanced gastric carcinoma

Ozguroglu M., Demir G.

CANCER , cilt.86, sa.3, ss.547-549, 1999 (SCI-Expanded, Scopus)

1999

334. Immunomodulating therapy with rIL-2 and interferon alpha induces in vivo expression of Bcl-2, Fas (APO-1/CD95), and Fas ligand on peripheral lymphocytes (A pilot study)

Demir G., Ozguroglu M., Sayhan N., Molinas-Mandel N., Demirelli F. H., Buyukunal E., et al.

ANTICANCER RESEARCH , cilt.19, ss.3517-3520, 1999 (SCI-Expanded, Scopus)

1999

335. Primary splenic tuberculosis in a patient with nasal angiocentric lymphoma - Mimicking metastatic tumor on abdominal CT

Ozguroglu M., Celik A. F., Demir G., Aki H., Demirelli F. H., Mandel N. K., et al.

JOURNAL OF CLINICAL GASTROENTEROLOGY , cilt.29, sa.1, ss.96-98, 1999 (SCI-Expanded, Scopus)

1999

336. Serum cardiolipin antibodies in cancer patients with thromboembolic events

Ozduroglu M., Arun B., Erzin Y., Demir G., Demirelli F., Mandel N., et al.

CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS , cilt.5, sa.3, ss.181-184, 1999 (SCI-Expanded, Scopus)

1999

337. Anaphylaxis from intraperitoneal infusion of cisplatin - A case report

Ozguroglu M., Demir G., Demirelli F. H., Mandel N. K.

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS , cilt.22, sa.2, ss.172-173, 1999 (SCI-Expanded, Scopus)

1999

338. Microangiopathic hemolytic anemia as an early predictor of recurrence in gastric cancer

Ozguroglu M., Demirelli F. H., Mandel N. K.

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS , cilt.22, sa.2, ss.214, 1999 (SCI-Expanded, Scopus)

1999

339. Unusual manifestations of B-cell disorders - Case 1: Multiple myeloma with predominant phalangeal involvement

Ozguroglu M., Akı H., Demir G., Demirelli F. H., Mandel N. K.

JOURNAL OF CLINICAL ONCOLOGY , cilt.17, sa.3, ss.1083-1084, 1999 (SCI-Expanded, Scopus)

1999

340. Uveal malign melanomlu olguların retrospektif değerlendirilmesi-tedavi yaklaşımı ve sonuçları

ÖZGÜROĞLU M., Pazarlı H., ÖZARAS R., Demir G., Tahan V., Demirelli F. H., et al.

AVICENA , cilt.1, ss.30-32, 1999 (Hakemli Dergi)

1999

341. Anaplastic large cell lymphoma of the duodenum fistulized to the colon: Leukocyte common antigen negativity leading to misdiagnosis as carcinoma

Ozguroglu M., Demir G., Dogysoy G., Korman U., Demirelli F., Mandel N., et al.

Journal of B.U.ON. , cilt.4, sa.2, ss.215-217, 1999 (SCI-Expanded, Scopus)

1999

342. Magnetic resonance imaging of bone marrow versus bone marrow biopsy in malignant lymphoma

Özgüroglu M., Ersavasti G. E., Demir G., Aki H., Demirelli F., Kanberoglu K., et al.

Pathology and Oncology Research , cilt.5, sa.2, ss.123-128, 1999 (SCI-Expanded, Scopus)

1999

343. Self expanding metal stents for palliation of dysphagia due to esophageal malignancies

Dobrucali A., Ozguroglu M., Demir G., Karahasanoglu T., Uzunismail H., Cebeci H., et al.

Turkish Journal of Gastroenterology , cilt.10, sa.1, ss.18-23, 1999 (SCI-Expanded, Scopus, TRDizin)

1998

344. A randomized phase III trial of etoposide, epirubicin, and cisplatin versus 5-fluorouracil, epirubicin, and cisplatin in the treatment of patients with advanced gastric carcinoma

Icli F., Celik I., Aykan F., Uner A., Demirkazik A., Ozet A., et al.

CANCER , cilt.83, sa.12, ss.2475-2480, 1998 (SCI-Expanded, Scopus)

1998

345. Kadınlarda primeri bilinmeyen aksiller karsinom metastazına yaklaşım: iki olgu bildirimi

ÖZGÜROĞLU M., Tahan V., ÖZARAS R., Demir G., Çerçel A., Demirelli F. H., et al.

Meme Hastalıkları Dergisi , cilt.5, ss.172-175, 1998 (Hakemli Dergi)

1998

346. High dose epirubicin and cisplatin induction chemotherapy sequentially followed by ifosfamide and etoposide chemotherapy in extensive stage small cell lung cancer (ES-SCLC)

Demirkazik A., Onat H., Saip P., Ozguroglu M., Kars A., Cay F., et al.

ANNALS OF ONCOLOGY , cilt.9, ss.105, 1998 (SCI-Expanded, Scopus)

1998

347. Immune effects of low-dose subcutaneous interleukin-2 in patients with metastatic malignant melanoma

Demir G., Demirelli F., Ozguroglu M., Molinas-Mandel N., Buyukunal E., Tuzuner N., et al.

INTERNATIONAL JOURNAL OF IMMUNOTHERAPY , cilt.14, sa.3, ss.163-168, 1998 (SCI-Expanded, Scopus)

1997

348. Magnetic resonance imaging of bone marrow versus biopsy in malignant lymphoma

Ozguroglu M., Ersavasti G., Demir G., Demirelli F., Tuzuner N., Kanberoglu K., et al.

EUROPEAN JOURNAL OF CANCER , cilt.33, ss.1220, 1997 (SCI-Expanded, Scopus)

1997

349. Generalized telangiectasia as the major manifestation of angiotropic (intravascular) lymphoma

Ozguroglu E., Buyulbabani N., Ozguroglu M., Baykal C.

BRITISH JOURNAL OF DERMATOLOGY , cilt.137, sa.3, ss.422-425, 1997 (SCI-Expanded, Scopus)

1996

350. The effects of tamoxifen on endometrium of patients with breast cancer Meme kanserli hastalarda tamoksifen tedavisinin yapmis oldugu endometriyum degisiklikleri

Kosebay D., Arvas M., Bese T., Demirkiran F., Mandel N., Ozguroglu M., et al.

Jinekoloji ve Obstetrik Dergisi , cilt.10, sa.2, ss.68-73, 1996 (Scopus)

1993

351. NORADRENERGIC AND SEROTONINERGIC DEPRESSION

YAZICI O., ARICIOGLU F., GURVIT G., UCOK A., TASTABAN Y., CANBERK O., et al.

JOURNAL OF AFFECTIVE DISORDERS , cilt.27, sa.2, ss.123-129, 1993 (SCI-Expanded, Scopus)

1991

352. Spontaneous improvement of tardive dystonia during mania

Yazici O., Kantemir E., Tastaban Y., Ucok A., Ozguroglu M.

British Journal of Psychiatry , cilt.158, ss.847-850, 1991 (SSCI, Scopus)

Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler

2025

1. Efficacy of olaparib (ola) plus abiraterone (abi) versus placebo (pbo) plus abi in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with a germline or somatic BRCA mutation in the PROpel trial.

Saad F., Armstrong A. J., Oya M., Shore N. D., Arslan C., Vianna K. C. M., et al.

American-Society-of-Clinical-Oncology: Genitourinary Cancers Symposium, San-Francisco, Kostarika, 13 - 15 Şubat 2025, cilt.43, (Özet Bildiri)

2024

2. Safety Profile of Durvalumab (D) as Consolidation Treatment (tx) in Limited -Stage Small -Cell Lung Cancer (LSSCLC) in ADRIATIC: Focus on Pneumonitis and Immune Mediated Adverse Events (imAEs)

Iyengar P., Cheng Y., Spigel D., Cho B. C., Laktionov K., Chen Y., et al.

66th International Conference on American-Society-for-Radiation-Oncology (ASTRO), Washington, Kiribati, 29 Eylül - 02 Ekim 2024, (Özet Bildiri)

2024

3. EFFICACY OF OLAPARIB PLUS ABIRATERONE VERSUS PLACEBO PLUS ABIRATERONE IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WITH A GERMLINE OR SOMATIC BRCA MUTATION IN THE PROPEL TRIAL

Shore N., Clarke N., Armstrong A. J., Oya M., Arslan C., Vianna K., et al.

Annual Meeting of the American-Urological-Association (AUA), San-Antonio, Kuzey Mariana Adaları, 3 - 06 Mayıs 2024, (Özet Bildiri)

2023

4. Phase 3 trial of durvalumab combined with domvanalimab following concurrent chemoradiotherapy (cCRT) in patients with unresectable stage III NSCLC (PACIFIC-8).

Ozguroglu M., Levy B. P., Horinouchi H., Yu J., Grainger E., Phuong P. H., et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 2 - 06 Haziran 2023, (Özet Bildiri)

2023

5. Health-related quality of life (HRQoL) and pain outcomes for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who received abiraterone (abi) and olaparib (ola) versus (vs) abi and placebo (pbo) in the phase III PROpel trial

Thiery-Vuillemin A., Saad F., Armstrong A. J., Oya M., Vianna K., Ozguroglu M., et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 2 - 06 Haziran 2023, (Özet Bildiri)

2023

6. Circulating tumor DNA (ctDNA) dynamics and survival outcomes in patients (pts) with advanced non-small cell lung cancer (aNSCLC) and high (>50%) programmed cell death-ligand 1 (PD-L1) expression, randomized to cemiplimab (cemi) vs chemotherapy (chemo)

Vokes N. I., Gandara D. R., Sezer A., Kilickap S., Gumus M., Bondarenko I., et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 2 - 06 Haziran 2023, (Özet Bildiri)

2022

7. 591 Immunogenicity of durvalumab: analysis of pooled pan-tumor data

El-Khoueiry A., Zhou D., Özgüroğlu M., Johnson M., Abou-Alfa G., Makowsky M., et al.

SITC 37th Annual Meeting (SITC 2022) Abstracts, Paris, Fransa, 13 - 16 Ekim 2022, ss.1, (Özet Bildiri)

2022

8. 582 Patient-reported outcomes with cemiplimab versus chemotherapy in advanced non-small cell lung cancer (aNSCLC): Eastern cooperative oncology group (ECOG) performance status subgroups in EMPOWER-Lung 1

Kilickap S., Sezer A., GümüŞ M., Bondarenko I., Özgüroğlu M., Gogishvili M., et al.

SITC 37th Annual Meeting (SITC 2022) Abstracts, Paris, Fransa, 3 - 04 Ekim 2022, ss.1-2, (Tam Metin Bildiri)

2022

9. Association between gene expression signatures and outcomes of pembrolizumab (pembro) and paclitaxel (pac) in advanced gastric cancer (GC): Exploratory analysis from KEYNOTE-061

Shitara K., Di Bartolomeo M., Mandala M., Ryu M., Caglevic C., Olesinski T., et al.

Annual Meeting of the American-Association-for-Cancer-Research (AACR), Louisiana, Amerika Birleşik Devletleri, 8 - 13 Nisan 2022, cilt.82, (Özet Bildiri)

2020

10. LAURA: Osimertinib maintenance following definitive chemoradiation therapy (CRT) in patients (pts) with unresectable stage III epidermal growth factor receptor mutation positive (EGFRm) non-small cell lung cancer (NSCLC)

Lu S., Casarini I., Kato T., Cobo Dols M., Ozguroglu M., Zeng L., et al.

ESMO Asia Virtual Congress, ELECTR NETWORK, 20 - 22 Kasım 2020, cilt.31, (Özet Bildiri)

2020

11. Durvalumab after chemoradiotherapy in stage III NSCLC: 4-year survival update from the phase III PACIFIC trial

Faivre-Finn C., Vicente D., Kurata T., Planchard D., Paz-Ares L., Vansteenkiste J. F., et al.

ESMO Virtual Congress, ELECTR NETWORK, 19 Eylül - 18 Ekim 2020, cilt.31, (Özet Bildiri)

2020

12. Tolerability of olaparib (OLA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: PROfound

Roubaud G., Ozguroglu M., Penel N., Matsubara N., Mehra N., Kolinsky M. P., et al.

ESMO Virtual Congress, ELECTR NETWORK, 19 Eylül - 18 Ekim 2020, cilt.31, (Özet Bildiri)

2020

13. Pembrolizumab (P) combined with chemotherapy (C) vs C alone as first-line (1L) therapy for advanced urothelial carcinoma (UC): KEYNOTE-361

Alva A., Csoszi T., Ozguroglu M., Matsubara N., Geczi L., Cheng S. Y., et al.

ESMO Virtual Congress, ELECTR NETWORK, 19 Eylül - 18 Ekim 2020, cilt.31, (Özet Bildiri)

2020

14. EMPOWER-Lung 1: Phase III first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) >= 50%

Sezer A., KILIÇKAP S., GÜMÜŞ M., Bondarenko I., Ozguroglu M., Gogishvili M., et al.

ESMO Virtual Congress, ELECTR NETWORK, 19 Eylül - 18 Ekim 2020, cilt.31, (Özet Bildiri)

2020

15. Final overall survival (OS) analysis of PROfound: Olaparib vs physician's choice of enzalutamide or abiraterone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations

de Bono J. S., Mateo J., Fizazi K., Saad F., Shore N., Sandhu S., et al.

ESMO Virtual Congress, ELECTR NETWORK, 19 Eylül - 18 Ekim 2020, cilt.31, (Özet Bildiri)

2020

16. Durvalumab (D) +/- tremelimumab (T) plus platinum-etoposide (EP) in 1L ES-SCLC: Characterization of long-term clinical benefit and tumour mutational burden (TMB) in CASPIAN

Goldman J. W., Garassino M. C., Chen Y., Reinmuth N., Hotta K., Poltoratskiy A., et al.

ESMO Virtual Congress, ELECTR NETWORK, 19 Eylül - 18 Ekim 2020, cilt.31, (Özet Bildiri)

2020

17. Impact of abiraterone acetate plus prednisone (AAP) in patients with castration-sensitive prostate cancer (mCSPC) and visceral metastases: Subgroup analyses of the LATITUDE study

Baciarello G., Ozguroglu M., Mundle S. D., Leitz G., Richarz U., Hu P., et al.

ESMO Virtual Congress, ELECTR NETWORK, 19 Eylül - 18 Ekim 2020, cilt.31, (Özet Bildiri)

2020

18. Albumin as a simple criterion to reduce early mortality (EM) in gastric cancer (GC) trials

Ozguroglu M., Shitara K., Lee K., Fuchs C. S., Chung H. C., Di Bartolomeo M., et al.

ESMO Virtual Congress, ELECTR NETWORK, 19 Eylül - 18 Ekim 2020, cilt.31, (Özet Bildiri)

2020

19. KEYNOTE-061: Response to subsequent therapy following second-line pembrolizumab or paclitaxel in patients with advanced gastric or gastroesophageal junction adenocarcinoma

Yoon H., Fuchs C., Ozguroglu M., Bang Y., Di Bartolomeo M., Mandala M., et al.

ESMO 22nd World Congress on Gastrointestinal Cancer, ELECTR NETWORK, 1 - 04 Temmuz 2020, cilt.31, (Özet Bildiri)

2020

20. APALUTAMIDE FOR METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER IN TITAN: PROGNOSTIC IMPORTANCE OF PROSTATE-SPECIFIC ANTIGEN RESPONSES

Chowdhury S., Bjartell A., Agarwal N., Chung B. H., Given R. W., Pereira de Santana Gomes A. J., et al.

Annual Meeting of the American-Urological-Association (AUA), Washington, Kiribati, 15 - 18 Mayıs 2020, cilt.203, (Özet Bildiri)

2020

21. PIVOT-10: A phase II study of bempegaldesleukin (NKTR-214) in combination with nivolumab (NIVO) in cisplatin (cis) ineligible patients with previously untreated locally advanced or metastatic urothelial cancer (mUC)

Huddart R. A., Siefker-Radtke A. O., Balar A. V., Bilen M. A., Powles T., Bamias A., et al.

Genitourinary Cancers Symposium of the American-Society-of-Clinical-Oncology (ASCO), San-Francisco, Kostarika, 13 - 15 Şubat 2020, cilt.38, (Özet Bildiri)

2020

22. Apalutamide (APA) for metastatic castration-sensitive prostate cancer (mCSPC) in TITAN: Outcomes in patients (pts) with low- and high-risk disease

Ozguroglu M., Chowdhury S., Bjartell A., Uemura H., Chung B. H., Agarwal N., et al.

Genitourinary Cancers Symposium of the American-Society-of-Clinical-Oncology (ASCO), San-Francisco, Kostarika, 13 - 15 Şubat 2020, cilt.38, (Özet Bildiri)

2020

23. Time to second progression (PFS2) in patients (pts) from TITAN with metastatic castration-sensitive prostate cancer (mCSPC) by first subsequent therapy (hormonal vs. taxane)

Agarwal N., Chowdhury S., Bjartell A., Chung B. H., Gomes A. J. P. d. S., Given R. W., et al.

Genitourinary Cancers Symposium of the American-Society-of-Clinical-Oncology (ASCO), San-Francisco, Kostarika, 13 - 15 Şubat 2020, cilt.38, (Özet Bildiri)

2020

24. Pembrolizumab (pembro) in microsatellite instability-high (MSI-H) advanced gastric/gastroesophageal junction (G/GEJ) cancer by line of therapy

Chao J., Fuchs C. S., Shitara K., Tabernero J., Muro K., Van Cutsem E., et al.

Gastrointestinal Cancers Symposium of the American-Society-of-Clinical-Oncology, San-Francisco, Kostarika, 23 - 25 Ocak 2020, cilt.38, (Özet Bildiri)

2020

25. PROfound: Efficacy of olaparib (ola) by prior taxane use in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations

De Bono J. S., Fizazi K., Saad F., Shore N. D., Roubaud G., Ozguroglu M., et al.

Genitourinary Cancers Symposium of the American-Society-of-Clinical-Oncology (ASCO), San-Francisco, Kostarika, 13 - 15 Şubat 2020, cilt.38, (Özet Bildiri)

2020

26. Results of the JAVELIN Gastric 100 phase 3 trial: avelumab maintenance following first-line (1L) chemotherapy (CTx) vs continuation of CTx for HER2-advanced gastric or gastroesophageal junction cancer (GC/GEJC)

Moehler M. H., Dvorkin M., Ozguroglu M., Ryu M., Muntean A. S., Lonardi S., et al.

Gastrointestinal Cancers Symposium of the American-Society-of-Clinical-Oncology, San-Francisco, Kostarika, 23 - 25 Ocak 2020, cilt.38, (Özet Bildiri)

2019

27. First-line durvalumab plus platinum-etoposide in extensive-stage (ES)-SCLC: Safety, pharmacokinetics (PK) and immunogenicity in CASPIAN

Ozguroglu M., Goldman J. W., Reinmuth N., Chen Y., Dvorkin M., Trukhin D., et al.

Immuno-Oncology Congress of the European-Society-for-Medical-Oncology (ESMO), Geneva, İsviçre, 11 - 14 Aralık 2019, cilt.30, ss.66, (Özet Bildiri)

2019

28. Immune-related adverse events associated with immune-checkpoint inhibitors: A single center experience

Samanci N., Oruc K., Bedir S., Celik E., Degerli E., Derin S., et al.

Immuno-Oncology Congress of the European-Society-for-Medical-Oncology (ESMO), Geneva, İsviçre, 11 - 14 Aralık 2019, cilt.30, (Özet Bildiri)

2019

29. Clinical efficacy of atezolizumab (atezo) in biomarker subgroups by SP142, SP263 and 22C3 PD-L1 immunohistochemistry (IHC) assays and by blood tumour mutational burden (bTMB): Results from the IMpower110 study

Herbst R. S., de Marinis F., Giaccone G., Reinmuth N., Vergnenegre A., Barrios C. H., et al.

Immuno-Oncology Congress of the European-Society-for-Medical-Oncology (ESMO), Geneva, İsviçre, 11 - 14 Aralık 2019, cilt.30, ss.62-63, (Özet Bildiri)

2019

30. Three-year overall survival update from the PACIFIC trial

Wu Y., Gray J. E., Villegas A., Daniel D. B., Vicente D., Murakami S., et al.

European-Society-for-Medical-Oncology (ESMO) Asia Congress, Singapore, Singapur, 22 - 24 Kasım 2019, cilt.30, (Özet Bildiri)

2019

31. Apalutamide (APA) plus androgen deprivation therapy (ADT) for metastatic castration-sensitive prostate cancer (mCSPC): Analysis of pain and fatigue in the TITAN study

Chung B. H., McQuarrie K., Bjartell A., Chowdhury S., Pereira de Santana Gomes A. J., Ozguroglu M., et al.

European-Society-for-Medical-Oncology (ESMO) Asia Congress, Singapore, Singapur, 22 - 24 Kasım 2019, cilt.30, (Özet Bildiri)

2019

32. Overall survival with first-line durvalumab plus platinum-etoposide in patients with extensive-stage (ES)-SCLC in CASPIAN: Subgroup findings from Asia

Nishio M., Ji J. H., Hotta K., Chiu C., Lee J., Azuma K., et al.

European-Society-for-Medical-Oncology (ESMO) Asia Congress, Singapore, Singapur, 22 - 24 Kasım 2019, cilt.30, (Özet Bildiri)

2019

33. IMvigor130: Efficacy and safety from a phase III study of atezolizumab (atezo) as monotherapy or combined with platinum-based chemotherapy (PBC) vs placebo plus PBC in previously untreated locally advanced or metastatic urothelial carcinoma (mUC)

Grande E., Galsky M., Arranz Arija J. A., De Santis M., Davis I. D., De Giorgi U. F. F., et al.

44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona, İspanya, 27 Eylül - 01 Ekim 2019, cilt.30, ss.888-889, (Özet Bildiri)

2019

34. Assessing the impact of subsequent checkpoint inhibitor (CPI) treatment on overall survival: Post hoc analyses from the phase III JAVELIN Lung 200 study of avelumab vs docetaxel in platinum-treated locally advanced/metastatic non-small cell lung cancer (NSCLC)

Barlesi F., Ozguroglu M., Vansteenkiste J. F., Spigel D., Yang J. C., Bajars M., et al.

44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona, İspanya, 27 Eylül - 01 Ekim 2019, cilt.30, (Özet Bildiri)

2019

35. PD-L1 expression, patterns of progression and patient-reported outcomes (PROs) with durvalumab plus platinum-etoposide in ES-SCLC: Results from CASPIAN

Paz-Ares L., Goldman J. W., Garassino M. C., Dvorkin M., Trukhin D., Statsenko G., et al.

44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona, İspanya, 27 Eylül - 01 Ekim 2019, cilt.30, ss.928-929, (Özet Bildiri)

2019

36. A challenging task - Identifying carcinoma of unknown primary (CUP) patients according to ESMO guidelines: The CUPISCO trial experience

Pauli C., Bochtler T., Mileshkin L., Baciarello G., Losa F., Ross J., et al.

44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona, İspanya, 27 Eylül - 01 Ekim 2019, cilt.30, (Özet Bildiri)

2019

37. Efficacy of durvalumab in patients with stage III NSCLC who experience pneumonitis (PACIFIC)

Vansteenkiste J. F., Naidoo J., Faivre-Finn C., Ozguroglu M., Villegas A., Daniel D., et al.

44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona, İspanya, 27 Eylül - 01 Ekim 2019, cilt.30, ss.592-593, (Özet Bildiri)

2019

38. Central, prospective detection of homologous recombination repair gene mutations (HRRm) in tumour tissue from > 4000 men with metastatic castration-resistant prostate cancer (mCRPC) screened for the PROfound study

de Bono J. S., Fizazi K., Saad F., Shore N., Sandhu S. K., Mehra N., et al.

44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona, İspanya, 27 Eylül - 01 Ekim 2019, cilt.30, ss.328-329, (Özet Bildiri)

2019

39. Impact of pembrolizumab (pembro) versus paclitaxel on health-related quality of life (HRQoL) in patients with advanced gastric or gastroesophageal junction (GEJ) cancer that has progressed after first-line chemotherapy (KEYNOTE-061)

Van Cutsem E., Amonkar M., Fuchs C. S., Alsina M., Ozguroglu M., Bang Y., et al.

44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona, İspanya, 27 Eylül - 01 Ekim 2019, cilt.30, ss.304, (Özet Bildiri)

2019

40. IMpower110: Interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD-L1-selected NSCLC

Spigel D., de Marinis F., Giaccone G., Reinmuth N., Vergnenegre A., Barrios C. H., et al.

44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona, İspanya, 27 Eylül - 01 Ekim 2019, cilt.30, ss.915, (Özet Bildiri)

2019

41. Patient-reported outcomes (PROs) from TITAN: A phase III, randomized, double-blind study of apalutamide (APA) versus placebo (PBO) added to androgen deprivation therapy (ADT) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC)

Agarwal N., McQuarrie K., Bjartell A., Chowdhury S., Gomes A. J. P. D. S., Chung B. H., et al.

44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona, İspanya, 27 Eylül - 01 Ekim 2019, cilt.30, (Özet Bildiri)

2019

42. Three-year overall survival update from the PACIFIC trial.

Gray J. E., Villegas A. E., Daniel D. B., Vicente D., Murakami S., Hui R., et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2019, cilt.37, (Özet Bildiri)

2019

43. First results from TITAN: A phase III double-blind, randomized study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT).

Chi K. N., Agarwal N., Bjartell A., Chung B. H., Gomes A. J. P. d. S., Given R. W., et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2019, cilt.37, (Özet Bildiri)

2019

44. Trifluridine/tipiracil (FTD/TPI) in patients (pts) aged >= 65 years with metastatic gastric/gastroesophageal junction cancer (mGC/mGEJC): Subgroup analysis from TAGS.

Shitara K., Doi T., Hosaka H., Thuss-Patience P. C., Santoro A., Jimenez-Fonseca P., et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2019, cilt.37, (Özet Bildiri)

2019

45. First subsequent treatment after discontinuation of durvalumab in unresectable, stage III NSCLC patients from PACIFIC.

Planchard D., Cho B. C., Gray J. E., Paz-Ares L. G., Ozguroglu M., Villegas A. E., et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2019, cilt.37, (Özet Bildiri)

2019

46. Final analysis of phase 3 LATITUDE study in patients (pts) with newly diagnosed high-risk metastatic castration-naive prostate cancer (NDx-HR mCNPC) treated with abiraterone acetate plus prednisone (AA plus P) added to androgen deprivation therapy (ADT)

Woo H., Fizaz K., Sulur G., Tran N., Fein L., Matsubara N., et al.

Annual Scientific Meeting of the Urological-Society-of-Australia-and-New-Zealand, Brisbane, Avustralya, 13 - 16 Nisan 2019, cilt.123, ss.27-28, (Özet Bildiri)

2019

47. Final analysis of phase III LATITUDE study in patients (pts) with newly diagnosed high-risk metastatic castration-naive prostate cancer (NDx-HR mCNPC) treated with abiraterone acetate plus prednisone (AA plus P) added to androgen deprivation therapy (ADT).

Fizazi K., Namphuong Tran N. T., Fein L. E., Matsubara N., Antolin A. R., Ozguroglu M., et al.

ASCO-SITC Clinical Immuno-Oncology Symposium, San-Francisco, Kostarika, 28 Şubat - 02 Mart 2019, cilt.37, (Özet Bildiri)

2018

48. PACIFIC: Overall Survival with Durvalumab versus Placebo after Chemoradiotherapy in Stage III NSCLC

Raben D., Faivre-Finn C., Spigel D., Daniel D., Villegas A., Vincente D., et al.

60th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO), San-Antonio, Kuzey Mariana Adaları, 21 - 24 Ekim 2018, cilt.102, ss.1607-1608, (Özet Bildiri)

2018

49. Phase III KEYNOTE-590 study of chemotherapy plus pembrolizumab versus chemotherapy plus placebo as first-line therapy for patients (Pts) with advanced esophageal or esophagogastric junction (E/EGJ) cancer

Kato K., Shah M. A., Enzinger P. C., Bennouna J., Shen L., Adenis A., et al.

43rd ESMO Congress (ESMO), Munich, Almanya, 19 - 23 Ekim 2018, cilt.29, (Özet Bildiri)

2018

50. LATITUDE study: PSA response characteristics and correlation with overall survival (OS) and radiological progression-free survival (rPFS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) receiving ADT plus abiraterone acetate and prednisone (AAP) or placebo (PBO)

Matsubara N., Chi K. N., Ozguroglu M., Rodriguez Antolin A., Feyerabend S., Fein L., et al.

43rd ESMO Congress (ESMO), Munich, Almanya, 19 - 23 Ekim 2018, cilt.29, (Özet Bildiri)

2018

51. Efficacy and safety evaluation based on time from completion of radiotherapy to randomization with durvalumab or placebo in pts from PACIFIC

Faivre-Finn C., Spigel D. R., Senan S., Langer C. J., Raben D., Perez B., et al.

43rd ESMO Congress (ESMO), Munich, Almanya, 19 - 23 Ekim 2018, cilt.29, ss.488, (Özet Bildiri)

2018

52. Phase I/II study of spartalizumab (PDR001), an anti-PD1 mAb, in patients with advanced melanoma or non-small cell lung cancer

Lin C., Taylor M., Boni V., Brunsvig P. F., Geater S. L., Salvagni S., et al.

43rd ESMO Congress (ESMO), Munich, Almanya, 19 - 23 Ekim 2018, cilt.29, ss.413, (Özet Bildiri)

2018

53. A phase 3 study of chemotherapy 1 pembrolizumab versus chemotherapy 1 placebo as first-line therapy for patients with advanced esophageal or esophagogastric junction (E/EGJ) cancer: KEYNOTE-590-Trial in progress

Kato K., Shah M., Enzinger P., Bennouna J., Shen L., Adenis A., et al.

ESMO 20th World Congress on Gastrointestinal Cancer, Barcelona, İspanya, 20 - 23 Haziran 2018, cilt.29, (Özet Bildiri)

2018

54. KEYNOTE-061: Phase 3 study of pembrolizumab vs paclitaxel for previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer

Shitara K., Ozguroglu M., Bang Y. J., Di Bartolomeo M., Mandala M., Ryu M. H., et al.

ESMO 20th World Congress on Gastrointestinal Cancer, Barcelona, İspanya, 20 - 23 Haziran 2018, cilt.29, (Özet Bildiri)

2018

55. An open-label, Multinational, Phase IIIb Study to Evaluate Patient and Satisfaction, Safety and Efficacy of Subcutaneous Administration of Trastuzumab in Patients With HER2-Positive Early Breast Cancer (ML28851) in Adjuvant/Neo-Adjuvant Setting

Cicin I., Oukkal M., Mahfouf H., Mezlini A., Larbaoui B., Slim B. A., et al.

11th European Breast Cancer Conference (EBCC), Barcelona, İspanya, 21 - 23 Mart 2018, cilt.92, (Özet Bildiri)

2018

56. JAVELIN Gastric 100: Phase 3 trial of avelumab (anti-PD-L1) maintenance therapy versus continuation of first-line chemotherapy in patients with advanced gastric or gastroesophageal junction cancer (GC/GEJC).

Moehler M. H., Ryu M., Lee K., Coskun H. S., Wong R., Ozguroglu M., et al.

Gastrointestinal Cancers Symposium, San-Francisco, Kostarika, 18 - 20 Ocak 2018, cilt.36, (Özet Bildiri)

2017

57. PACIFIC: A Double-Blind, Placebo-Controlled Phase 3 Study of Durvalumab as Consolidation Therapy After Chemoradiation in Patients with Locally Advanced, Unresectable Non-Small Cell Lung Cancer

Antonia S. J., Villegas A., Daniel D., Baz D. V., Murakami S., Hui R., et al.

59th Annual Meeting of the American-Society-for-Therapeutic-Radiation-Oncology (ASTRO), California, Amerika Birleşik Devletleri, 24 - 27 Eylül 2017, cilt.99, ss.1314-1315, (Özet Bildiri)

2017

58. PACIFIC: A double-blind, placebo-controlled phase III study of durvalumab after chemoradiation therapy (CRT) in patients with stage III, locally advanced, unresectable NSCLC

Paz-Ares L., Villegas A., Daniel D., Baz D. V., Murakami S., Hui R., et al.

42nd European-Society-for-Medical-Oncology Congress (ESMO), Madrid, İspanya, 8 - 12 Eylül 2017, cilt.28, (Özet Bildiri)

2017

59. JAVELIN Lung 100: updated design of a phase 3 trial of aveiumab vs platinum doublet chemotherapy as first-line (1L) treatment for metastatic or recurrent PD-L1+non-small-cell lung cancer (NSCLC)

Reck M., Yang C., Postmus P. E., Barlesi F., Font E. F., Thomas M., et al.

42nd European-Society-for-Medical-Oncology Congress (ESMO), Madrid, İspanya, 8 - 12 Eylül 2017, cilt.28, (Özet Bildiri)

2017

60. Everolimus (EVE) plus letrozole (LET) in patients (pts) with estrogen receptor-positive (ER plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Progression-free survival (PFS) subgroup analyses in BOLERO-4

Bachelot T., Royce M., Villanueva C., Melo Cruz F., Hegg R., Falkson C., et al.

42nd European-Society-for-Medical-Oncology Congress (ESMO), Madrid, İspanya, 8 - 12 Eylül 2017, cilt.28, (Özet Bildiri)

2017

61. LATITUDE: A phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer

Fizazi K., Tran N., Fein L. E., Matsubara N., Antolin A. R., Alekseev B. Y., et al.

53rd Annual Clinical Science Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Symposium on Old Targets, New Drugs - Her2 and MET, Illinois, Amerika Birleşik Devletleri, 2 - 07 Haziran 2017, cilt.35, (Özet Bildiri)

2017

62. Everolimus (EVE) plus endocrine therapy in patients with estrogen receptor-positive (ER plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (BC): First-and second-line data from the BOLERO-4 study.

Cardoso F., Villanueva C., Royce M., Cruz F., Debled M., Hegg R., et al.

53rd Annual Clinical Science Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Symposium on Old Targets, New Drugs - Her2 and MET, Illinois, Amerika Birleşik Devletleri, 2 - 07 Haziran 2017, cilt.35, (Özet Bildiri)

2016

63. Stomatitis in patients treated with first-line everolimus (EVE) plus letrozole (LET): Results from BOLERO-4 trial

Villanueva C., Tsugawa K., Toyama T., Noh W., Jeong J., Cardoso F., et al.

San Antonio Breast Cancer Symposium, San-Antonio, Kuzey Mariana Adaları, 6 - 10 Aralık 2016, cilt.77, (Özet Bildiri)

2016

64. BOLERO-4: Phase 2 trial of first-line everolimus (EVE) plus letrozole (LET) in estrogen receptor-positive (ER plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (BC)

Royce M., Villanueva C., Ozguroglu M., Bachelot T., Azevedo S., Melo Cruz F., et al.

41st Annual Congress of the European-Society-for-Medical-Oncology (ESMO), Copenhagen, Danimarka, 7 - 11 Ekim 2016, cilt.27, (Özet Bildiri)

2016

65. TITAN: A randomized, double-blind, placebo-controlled, phase 3 trial of apalutamide (ARN-509) plus androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC)

Chi K. N., Chowdhury S., Radziszewski P., Lebret T., Ozguroglu M., Sternberg C., et al.

41st Annual Congress of the European-Society-for-Medical-Oncology (ESMO), Copenhagen, Danimarka, 7 - 11 Ekim 2016, cilt.27, (Özet Bildiri)

2016

66. Avelumab (MSB0010718C; anti-PD-L1) vs platinum-based doublet as first-line treatment for metastatic or recurrent PD-L1-positive non-small-cell lung cancer: The phase 3 JAVELIN Lung 100 trial.

Reck M., DeGreen H. P., Rose A. L., Pavlakis N., Derjcke S. M., Radic J., et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 3 - 07 Haziran 2016, cilt.34, (Özet Bildiri)

2015

67. Everolimus plus trastuzumab and vinorelbine for trastuzumabresistant, taxane-pretreated, HER2+advanced breast cancer: Overall survival results from BOLERO-3

Isaacs C., O'Regan R., Xu B., Masuda N., Arena F., Yap Y., et al.

38th Annual CTRC-AACR San Antonio Breast Cancer Symposium, San-Antonio, Kuzey Mariana Adaları, 8 - 12 Aralık 2015, cilt.76, (Özet Bildiri)

2015

68. Prognositic value of baseline neutrphil to lymphocyte ratio in metastatic urothelial cancer patients treated with first line chmotherapy A large retrospective muticenter study

Auvray M., Elaidi R., ÖZGÜROĞLU M., Güven S., Gauthier H., Culine S., et al.

ECCO 2015, viyana, Avusturya, 20 - 23 Ekim 2015

2015

69. Prognostic value of baseline Neutrophil to Lymphocyte Ratio (NLR) in metastatic Urothelial Carcinomas (mUC) patients (pts) treated with first-line chemotherapy (CT): A large retrospective multicenter study

Auvray M., Elaidi R., Ozguroglu M., Guven S., Gauthier H., Culine S., et al.

European Cancer Congress, Vienna, Avusturya, 01 Ocak 2015, cilt.51, (Özet Bildiri)

2015

70. Response to cabazitaxel in patients with metastatic castration-resistant prostate cancer (mCRPC) poorly responding to docetaxel

Angelergues A., Bellmunt J., Efstathiou E., Gonzalez I., Gyftaki R., Delanoy N., et al.

European Cancer Congress / 18th Meeting of the European-Cancer-Organization (ECCO) / 40th Meeting of the European-Society-for-Medical-Oncology (ESMO), Vienna, Avusturya, 25 - 29 Eylül 2015, cilt.51, (Özet Bildiri)

2015

71. Treatment patterns in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel (DOC)-based chemotherapy (CT): PROXIMA 1-year analysis

Akaza H., Procopio G., Pripatnanont C., Facchini G., Fava S., Wheatley D., et al.

European Cancer Congress, Vienna, Avusturya, 01 Ocak 2015, cilt.51, (Özet Bildiri)

2015

72. Updated results of the FLAC European database of metastatic castration resistant prostate cancer (mCRPC) patients (pts) treated with life extending therapies in post-docetaxel (D) setting

Oudard S., Angelergues A., Efstathiou E., Gonzalez I., Gyftaki R., Delanoy N., et al.

European Cancer Congress, Vienna, Avusturya, 01 Ocak 2015, cilt.51, (Özet Bildiri)

2015

73. Clinical experience with vemurafenib in pretreated melanoma The results of open label multicenter study from Turkey

ÇELİK İ., Molinas Mandel N., GÖKMEN E., Olcun Ü. Ü., SEVİNÇ A., COŞKUN H. Ş., et al.

ASCO annual meeting, 29 Mayıs - 02 Haziran 2015

2015

74. Clinical experience with Vemurafenib in pretreated melanoma (MEL): The results of open label multi center study from Turkey

Celik I., Mandel N. M., Gokmen E., Unal O. U., Sevinc A., Coskun H. S., et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, Amerika Birleşik Devletleri, 29 Mayıs - 02 Haziran 2015, cilt.33, (Özet Bildiri)

2014

75. Duration of response to androgen-deprivation therapy (ADT) and efficacy of secondary hormone therapy, docetaxel (D), and cabazitaxel (C) in metastatic castration-resistant prostate cancer (mCRPC).

Angelergues A., Maillet D., Flechon A., Ozguroglu M., Mercier F., Guillot A., et al.

Genitourinary Cancers Symposium, San-Francisco, Kostarika, 30 Ocak - 01 Şubat 2014, cilt.32, (Özet Bildiri)

2013

76. Clinical significance of p95HER2 Overexpression, PTEN loss and PI3K expression in p185HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies

Tural D., Demirelli F., Serdengecti S., ÖZTÜRK T., Ilvan S., Turna H., et al.

European Cancer Congress 2013 - 17th ECCO / 38th ESMO / 32nd ESTRO, Amsterdam, Hollanda, 27 Eylül - 01 Ekim 2013, cilt.49, (Özet Bildiri)

2013

77. ER/PR/HER2 receptor discordance between primary tumors and corresponding axillary metastases in curatively resected node positive breast cancer patients

Ozturk M., Turna H., Aydin O., Tural D., Demirelli F., Ozguroglu M., et al.

European Cancer Congress 2013 - 17th ECCO / 38th ESMO / 32nd ESTRO, Amsterdam, Hollanda, 27 Eylül - 01 Ekim 2013, cilt.49, (Özet Bildiri)

2013

78. Prognostic factors of survival in patients with metastatic castration resistant prostate cancer (mCRPC) treated with cabazitaxel: Sequencing might matter

Angelergues A., Maillet D., Flechon A., Ozguroglu M., Mercier F., Guillot A., et al.

49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2013, cilt.31, (Özet Bildiri)

2013

79. Phase III, randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and vinorelbine in trastuzumab-resistant, advanced breast cancer (BOLERO-3).

O'Regan R., Ozguroglu M., Andre F., Toi M., Jerusalem G. H. M., Wilks S., et al.

49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2013, cilt.31, (Özet Bildiri)

2012

80. IMPACT OF CABAZITAXEL (CBZ) plus PREDNISONE (P; CBZP) ON OVERALL SURVIVAL (OS) AT 2 YRS AND IN PATIENTS (PTS) WITH AGGRESSIVE DISEASE: POST-HOC ANALYSES OF TROPIC TRIAL

Oudard S., de Bono J. S., Ozguroglu M., Hansen S., Machiels J., Kocak I., et al.

37th Congress of the European-Society-for-Medical-Oncology (ESMO), Vienna, Avusturya, 28 Eylül - 02 Ekim 2012, cilt.23, ss.307-308, (Özet Bildiri)

2012

81. Thromboembolic complications in cancer patients.

Yenidunya G., Turna H., Ozturk M. A., Tural D., Selcukbiricik F., Yildiz O., et al.

48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 1 - 06 Haziran 2012, cilt.30, (Özet Bildiri)

2012

82. A cohort compassionate-use program with cabazitaxel plus prednisone for patients with metastatic castration-resistant prostate cancer: Interim results.

Bavbek S. E., Malik Z. I., Di Lorenzo G., Scholz H., van Oort I. M., Siobhan Ng S. N., et al.

48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 1 - 06 Haziran 2012, cilt.30, (Özet Bildiri)

2012

83. NOD POZİTİF MEME KANSERLERİNDE PRİMER TÜMÖR VE AKSİLLER METASTAZIN ER, PR VE HER2 EKSPRESYONU AÇISINDAN KARŞILAŞTIRILMASI

ÖZTÜRK M. A., AYDIN Ö., İLVAN Ş., TURNA Z. H., TURAL D., YILDIZ Ö., et al.

4. TIBBİ ONKOLOJİ KONGRESİ, Antalya, Türkiye, 21 - 25 Mart 2012, ss.103, (Özet Bildiri)

2011

84. Preoperative Chemoradiotherapy Improves Local Recurrence Free Survival in Locally Advanced Rectal Cancer

Turhal D., Ozturk M. A., Yildiz O., Selcukbiricik F., Elicin O., Erguney S., et al.

European Multidisciplinary Cancer Congress on Integrating Basic and Translational Science, Surgery, Radiotherapy, Medical oncology, Advocacy and Care, Stockholm, İsveç, 23 - 27 Eylül 2011, cilt.47, (Özet Bildiri)

2011

85. Tumour Characteristics Determining Response to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer

Turna Z. S., Ozturk M. A., Tural D., Biricik F. S., Yildiz O., Ozguroglu M., et al.

European Multidisciplinary Cancer Congress on Integrating Basic and Translational Science, Surgery, Radiotherapy, Medical oncology, Advocacy and Care, Stockholm, İsveç, 23 - 27 Eylül 2011, cilt.47, (Özet Bildiri)

2011

86. KRas and Braf: Is a Predictor in Metastatic Colorectal Cancer Patients for Bevacizumab?

Selcukbiricik F., Yildiz O., Tural D., Ozturk M. A., Demir G., Ozguroglu M., et al.

European Multidisciplinary Cancer Congress on Integrating Basic and Translational Science, Surgery, Radiotherapy, Medical oncology, Advocacy and Care, Stockholm, İsveç, 23 - 27 Eylül 2011, cilt.47, (Özet Bildiri)

2011

87. Cabazitaxel Plus Prednisone for Patients With Metastatic Castration-resistant Prostate Cancer Previously Treated With a Docetaxel-containing Regimen - Interim Analysis Results From an Ongoing Compassionate-use Programme

Heidenreich A., Scholz H. J., van Oort I., Bavbek S., Mueller S., Ozguroglu M., et al.

European Multidisciplinary Cancer Congress on Integrating Basic and Translational Science, Surgery, Radiotherapy, Medical oncology, Advocacy and Care, Stockholm, İsveç, 23 - 27 Eylül 2011, cilt.47, (Özet Bildiri)

2010

88. INCREASING ROLE OF METASTASECTOMY IN METASTATIC BREAST CANCER PATIENTS: WHO BENEFITS MORE

Selcukbiricik F., Ozguroglu M., Öztürk M. S., Turna H., Tural D., Yildiz O., et al.

35th European-Society-for-Medical-Oncology (ESMO) Congress, Milan, İtalya, 8 - 12 Ekim 2010, cilt.21, ss.111, (Özet Bildiri)

2010

89. THE EFFECTS OF PATIENT AND TUMOR CHARECTERISTICS AND TREATMENT MODALITIES ON PROGNOSIS OF PATIENTS WITH UVEAL MELANOMA

Tural D., Ozguroglu M., Turna H., Selcukbiricik F., Ozturk M. A., Sevinc M., et al.

35th European-Society-for-Medical-Oncology (ESMO) Congress, Milan, İtalya, 8 - 12 Ekim 2010, cilt.21, ss.406, (Özet Bildiri)

2010

90. CABAZITAXEL PLUS PREDNISONE/PREDNISOLONE SIGNIFICANTLY INCREASES OVERALL SURVIVAL COMPARED TO MITOXANTRONE PLUS PREDNISONE/PREDNISOLONE IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) PREVIOUSLY TREATED WITH DOCETAXEL: FINAL RESULTS WITH UPDATED OVERALL SURVIVAL OF A MULTINATIONAL PHASE III TRIAL (TROPIC)

Oudard S. M., De Bono J. S., Ozguroglu M., Hansen S., Machiels J., Shen L., et al.

35th European-Society-for-Medical-Oncology (ESMO) Congress, Milan, İtalya, 8 - 12 Ekim 2010, cilt.21, ss.272, (Özet Bildiri)

2009

91. The effects of prognostic factors on the first recurrence patterns of breast cancer

Turna H., Ozguroglu M., Demir G., Mandel N., Ilvan S., Calay Z., et al.

15th Congress of the European-Cancer-Organization/34th Multidisciplinary Congress of the European-Society-for-Medical-Oncology, Berlin, Almanya, 20 - 24 Eylül 2009, cilt.7, ss.312, (Özet Bildiri)

2009

92. Is there any future of prophylactic cranial irradiation in adenocarcinoma of the lung?

Ozguroglu M., Turna H., Sevinc M., Karaaslan S., Gursu U. R.

15th Congress of the European-Cancer-Organization/34th Multidisciplinary Congress of the European-Society-for-Medical-Oncology, Berlin, Almanya, 20 - 24 Eylül 2009, cilt.7, ss.534, (Özet Bildiri)

2008

93. AWARENESS OF CANCER DIAGNOSIS IN TURKISH CANCER PATIENTS AND ATTITUDES OF PHYSICIANS AND NURSES TOWARDS DISCLOSURE OF THE DIAGNOSIS

Sayilir A., Ozguroglu M., Turna H.

33rd European-Society-for-Medical-Oncology Congress, Stockholm, İsveç, 12 - 16 Eylül 2008, cilt.19, ss.263, (Özet Bildiri)

2008

94. MULTICENTER, PHASE II STUDY OF LAROTAXEL IN PATIENTS (PTS) WITH METASTATIC BREAST CANCER (MBC) PROGRESSING AFTER ANTHRACYCLINES, TAXANES AND CAPECITABINE

Ozguroglu M., Mansutti M., Kerr R., Awada A., Rha S. Y., Im Y. H., et al.

33rd European-Society-for-Medical-Oncology Congress, Stockholm, İsveç, 12 - 16 Eylül 2008, cilt.19, ss.69, (Özet Bildiri)

2008

95. CHARACTERISTICS OF THROMBOEMBOLIC COMPLICATIONS IN CANCER PATIENTS

Turna H., Ozguroglu M., Guersu R. U., Karaaslan S., Yildiz O., Yanmaz M. T.

33rd European-Society-for-Medical-Oncology Congress, Stockholm, İsveç, 12 - 16 Eylül 2008, cilt.19, ss.256-257, (Özet Bildiri)

2006

96. Imatinib mesylate response in Gastrointestinal Stromal Tumors: Experience of cerrahpasa medical faculty

Yildiz I., Mandel N. M., Demir G., Ozguroglu M., Toptas T., Buyukunal E., et al.

31st Congress of the European-Society-for-Medical-Oncology, İstanbul, Türkiye, 29 Eylül - 03 Ekim 2006, cilt.17, ss.164, (Özet Bildiri)

2006

97. Trastuzumab beyond progression in metastatic breast cancer

Yanmaz M. T., Ozguroglu M., Ozturk B., Uygun K., Basaran G., Turna H., et al.

31st Congress of the European-Society-for-Medical-Oncology, İstanbul, Türkiye, 29 Eylül - 03 Ekim 2006, cilt.17, ss.77, (Özet Bildiri)

2006

98. Phase II trial of a combination of weekly docetaxel and four-weekly carboplatin in the first-line treatment of advanced non-small cell lung cancer (NSCLC)

Ozguroglu M., Evrensel T., Er O., Turna H., Yanmaz T., Yildiz O., et al.

31st Congress of the European-Society-for-Medical-Oncology, İstanbul, Türkiye, 29 Eylül - 03 Ekim 2006, cilt.17, ss.225, (Özet Bildiri)

2004

99. The evaluation of toxicity and survival results of a phase II trial investigating the role of postoperative chemoradioimmunotherapy for gastric adenocarcinoma

Bese N., Yildirim A., Ober A., Ozguroglu M., Mandel N., Demir G., et al.

23rd Annual Meeting of the European-Society-for-Therapeutic-Radiology-and-Oncology (ESTRO 23), Amsterdam, Hollanda, 24 - 28 Ekim 2004, cilt.73, (Özet Bildiri)

2004

100. Is the incidence of anal canal cancers different in Moslem societies?

Cabuk D., Yumuk P., Abacioglu U., Demir G., Dane F., Gumus M., et al.

40th Annual Meeting of the American-Society-of-Clinical-Oncology, Louisiana, Amerika Birleşik Devletleri, 5 - 08 Haziran 2004, cilt.22, (Özet Bildiri)

2004

101. Gastric cancer in Turkey: A single center experience of 683 cases

Demir G., Buyukunal E., Kizilkilic E., Ozguroglu M., Mandel N., Demirelli F., et al.

40th Annual Meeting of the American-Society-of-Clinical-Oncology, Louisiana, Amerika Birleşik Devletleri, 5 - 08 Haziran 2004, cilt.22, (Özet Bildiri)

2004

102. The acute phase proteins in cancer patients

Bolayirli I., Ozguroglu M., Balci H., Orhanoglu T., Hacibekiroglu M.

56th Annual Meeting of the American-Association-for-Clinical-Chemistry, Los-Angeles, Şili, 25 - 29 Temmuz 2004, cilt.50, (Özet Bildiri)

2003

103. Expression of MMP-1 MMP-2 MMP-9 TIMP -1 VEGF in patients with colrectal neuroendocrine tumors

Demir O. G., Büyükünal E., Yirmibeşcik S., Doğusoy G., Turna Z. H., Özgüroğlu M., et al.

ASCO 39th Annual meeting 2003, Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 03 Haziran 2003, ss.336, (Özet Bildiri)

2003

104. Nonalcholic fatty liver disease (NAFLD)associated with breast cancer

Bilici A., Özgüroğlu M., Mihmanlı İ., Turna Z. H., Adaletli İ., Serdengeçti S.

ASCO 39th annual meeting 2003, Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 03 Haziran 2003, ss.254, (Özet Bildiri)

2002

105. Retrospective Analysis of rectal cancer patients in Turkey (212 cases)

Demir O. G., Büyükünal E., Ayata E., Karahasanoğlu T., Turna Z. H., Aykın A., et al.

ASCO 38th Annual meeting, Florida, Amerika Birleşik Devletleri, 18 - 21 Mayıs 2002, ss.127, (Özet Bildiri)

2002

106. The ımpact of Prognostic Factors on the recurrence patterns of breast cancer : a retrospective analysisi of 1276 patients

Turna Z. H., Srdengeçti S., Özgüroğlu M., Demir O. G., Demirelli F. H., Molinas Mandel N., et al.

ASCO 38th Annual meeting 2002, Florida, Amerika Birleşik Devletleri, 19 - 21 Mayıs 2002, ss.50, (Özet Bildiri)

2002

107. Effects of tumor angiogenesis and Bcl-2expression on response to therapy and survival in advanced gastric cancer

Erzin Y., Molinas Mandel N., Demir O. G., Özgüroğlu M., Okkan S., Turna Z. H., et al.

ASCO 38th annual meeting 2002, Florida, Amerika Birleşik Devletleri, 18 - 21 Mayıs 2002, ss.126, (Özet Bildiri)

2002

108. Neuroendocrine lung carcinomas:small cell cancer versus nonsmallcell lung cancer with neuroendocrine differentiation

Özgüroğlu M., Serdengeçti S., Kaya S., Turna Z. H., Öz B., Demir O. G., et al.

ASCO 38th annual meeting 2002, Florida, Amerika Birleşik Devletleri, 18 - 21 Mayıs 2002, ss.330, (Özet Bildiri)

1999

109. Significance of serum beta-2 microglobulin in epithelial ovarian cancer

ÖZGÜROĞLU M., Tahan V., Demir G., ÖZARAS R., Demirelli F. H., Mandel N. M., et al.

35th Annual Meeting , American Society of Clinical Oncology., Atlanta, Amerika Birleşik Devletleri, 15 - 18 Mayıs 1999, cilt.1, ss.382, (Tam Metin Bildiri)

1999

110. Uveal Malign Melanomlu Olguların Retrospektif Değerlendirilmesi-tedavi Yaklaşımı ve Sonuçları

ÖZGÜROĞLU M., Demir G., ÖZARAS R., Tahan V., Pazarlı H., Demirelli F. H., et al.

XIII. Ulusal Kanser Kongresi, Antalya, Türkiye, 27 Nisan - 01 Mayıs 1999, cilt.1, ss.310, (Tam Metin Bildiri)

1998

111. Chemoimmunotherapy protocol in patients with advanced gastric cancer

Demir G., Ozguroglu M., Belentepe S., Demirelli F., Mandel N., Buyukunal E., et al.

2nd Congress of the Balkan-Union-of-Oncology, İzmir, Türkiye, 10 - 14 Eylül 1998, ss.407-411, (Tam Metin Bildiri)

1996

112. THE ROLE OF LOCAL RADIATION THERAPY IN NEOADJUVANT PROTOCOL OF OSTEOSARCOMA

Uzel M., HIZ V. M. M., AYDINGÖZ Ö., Okkan S., KOCA S. S., Molinas N., et al.

2ND OSTEOSARCOMA RESEARCH CONFERENCE ABSTRACT BOOK, İtalya, 1 - 04 Kasım 1996, ss.21, (Özet Bildiri)

Bilimsel Dergilerdeki Faaliyetler

2022 - Devam Ediyor

FRONTIERS IN IMMUNOLOGY

Editör

2021 - Devam Ediyor

LIFE RESEARCH

Değerlendirme Kurul Üyesi

Bilimsel Kuruluşlardaki Üyelikler / Görevler

2017 - Devam Ediyor

FACULTY MEMBER of genitourinary cancers in ESMO

Danışma Kurulu Üyesi

2013 - Devam Ediyor

BOLERO 4 ÇALIŞMASINDA STEERING COMMITTE ÜYELİĞİ

Yönetim Kurulu Üyesi

2012 - Devam Ediyor

PROXIMA ÇALIŞMASINDA STEERING COMMITTEE ÜYELİĞİ

Yönetim Kurulu Üyesi

2021 - 2021

ESMO 2021

Bilim Kurulu Üyesi